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Glucocorticoid induction of growth hormone in anterior pituitary cells of 
embryonic chickens is an indirect effect. A genome-wide microarray screen conducted on 
embryonic day 11 chickens identified Dexras1 as a novel candidate gene involved in 
mediating the glucocorticoid effects on GH mRNA expression. The following studies 
were aimed at characterizing glucocorticoid regulation of chicken Dexras1 and 
identifying potential involvement of Dexras1 in mediating glucocorticoid effects on GH 
expression. We determined that glucocorticoid induction of Dexras1 requires 
glucocorticoid receptor and both MEK1/2 and Ras cell signalling pathways. 
Overexpression of Dexras1 vector had no effect on GH reporter activity. Transfection of 
10ng or 100ng of Dexras1 expression plasmid stimulated basal GH mRNA levels, 
  
whereas transfection of 1000ng of Dexras1 expression plasmid significantly inhibited 
levels of glucocorticoid-induced GH mRNA. YFP-tagged Dexras1 protein was 
predominantly found in the cytoplasm and glucocorticoid treatment did not cause 
Dexras1 to translocate to the plasma membrane. Downstream targets of Dexras1 are not 
known. Additionally, glucocorticoid-regulated histone modifications within 2kb of the 
GH gene were investigated using chromatin immunoprecipitation assays. The effects of 
glucocorticoid (1.5 h or 6 h) on histone H3 modifications, RNA Polymerase II (Pol II) 
recruitment, and association of GR, Pit-1, and Ets1 with the chicken GH gene were 
examined. We found increased H3 acetylation and tri-methylation of lysine 4 at both Pit-
1 sites and the transcription start site (TSS) in response to 1.5 h glucocorticoid treatment. 
Furthermore, 1.5 h glucocorticoid treatment significantly increased recruitment of Pit-1 
and Pol II to the proximal Pit-1 site and the TSS, respectively. GR was recruited to the 
glucocorticoid-responsive region (GCRR) and the distal Pit-1 site in response to 1.5 h 
glucocorticoid treatment, while 6 h glucocorticoid treatment resulted in Ets1 dissociation 
from the GCRR. Collectively, these results indicate that glucocorticoid induces dynamic 
changes in histone modifications and transcription factor recruitment within the 5‘-
flanking region of the chicken GH gene. We conclude that glucocorticoid induction of 
GH gene expression in chickens is achieved by a combination of genomic and 
nongenomic pathways. Our studies provide novel mechanisms of GH regulation in 
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The proper differentiation of the anterior pituitary gland into five distinct 
hormone-producing cell types and the establishment of the hypothalamus-pituitary axis is 
a fundamental process that is necessary for proper development of vertebrate organisms. 
The hypothalamus-pituitary structure and the process of pituitary development are highly 
conserved among birds, rodents, and other vertebrate species. In humans, developmental 
defects of the pituitary gland result in one or more hormone deficiencies, further leading 
to other abnormalities (2). 
Glucocorticoids are important steroid hormones produced by the adrenal cortex 
that have several physiological roles including the regulation of metabolism, immune 
functions, and the stress response. Glucocorticoids have long been identified to be 
required for the maintenance of secretory functions of certain endocrine and exocrine 
organs. In addition, glucocorticoids play a crucial role in the terminal differentiation of 
several tissues including liver, lung, small intestine, and pancreas. In the anterior 
pituitary, glucocorticoids have been shown to be important for the production of growth 
hormone (GH).  
Remarkable progress has been made in understanding the molecular mechanisms 
controlling pituitary development. This process involves a complex network of 
transcription factors and epigenetic modifiers that are tightly regulated to achieve spatio-
temporal differentiation of the five hormone-producing cell types. Despite this progress, 
the factors necessary for the cell-type specification and the molecular details of the 





Pituitary development and differentiation 
The pituitary gland, or hypophysis, is an endocrine gland located underneath the 
hypothalamus at the base of the brain. It is composed of two lobes: the anterior pituitary 
(or adenohypophysis) and the posterior pituitary (or neurohypophysis) (3). The 
hypothalamus is connected to the pituitary gland through the infundibular stem (or 
pituitary stalk). The pituitary gland is controlled by the hypothalamus. The axonal 
projections originating from the supraoptic and paraventricular nuclei of the 
hypothalamus terminate in the posterior pituitary, and hypthalamic stimulations by way 
of these neurons control the secretion of hormones from the posterior pituitary (4). The 
anterior pituitary is connected to the hypothalamus by an elaborate vascular pathway 
called the hypothalamic-hypophyseal portal veins. The hypothalamic factors synthesized 
in the parvocellular neurons of the hypothalamus are transported through the portal 
system to the anterior pituitary, and these factors regulate the secretion of the anterior 
pituitary hormones (3-5).  
Anterior pituitary development 
The pituitary structure and development are highly conserved among vertebrates. 
The anterior and posterior pituitary tissues have distinct embryological origins (6). 
During development, a finger-like upward projection of the oral ectoderm forms Rathke‘s 
pouch. This pouch develops into the anterior pituitary (7, 8) (Fig 1). A second finger-like 
projection extends ventrally from the diencephalon, and this develops into the posterior 
pituitary. Cell-cell contact between the ventral diencephalon and Rathke‘s pouch is 








Figure 1. Pituitary development from Rathke‘s pouch and differentiation of the hormone-
producing cell types in the anterior pituitary and intermediary lobe. Also shown are some 
of the transcription factors that are involved in the differentiation process. Figure taken 
from Quereda, et al. (10).  
 
The opposing signalling cascade formed by the diencephalon cells producing 
bone morphogenetic protein 4(BMP4), wingless-type MMTV integration site family, 
member 5A (WNT5a), and several fibroblast growth factors (FGFs) and the oral 
ectoderm cells secreting sonic hedgehog (Shh) is essential for the positional 
determination of the pituitary cell types (9, 11). Expression of FGF8 in the diencephalon 




homeobox 3 (Lhx3) (12). Lhx3 is required for determination and differentiation of 
pituitary cell lineages.   
The anterior pituitary differentiates into five distinct hormone-secreting cell types, 
each of which is biochemically distinct from each other (13) (Fig 1). Corticotrophs 
produce the adrenocorticotrophic hormone (ACTH), which stimulates the synthesis of 
glucocorticoids in the adrenal cortex. Somatotrophs produce GH, which is important for 
long bone development and muscle growth. Lactotrophs produce prolactin (PRL) that 
regulates lactation: Thyrotrophs produce thyroid-stimulating hormone (TSH) that 
stimulates the thyroid gland to produce thyroid hormone, and gonadotrophs produce 
luteinizing hormone (LH) (14) and follicle-stimulating hormone (FSH), which are 
essential for reproduction. Theses hormone-secreting cell types appear sequentially 
during development in the anterior pituitary. Corticotrophs are the first cell type to 
appear, followed by gonadototrophs, thyrotrophs, somatotrophs, and finally lactotrophs 
(4, 15, 16). The different cell types also have distinct regional distribution within the 
anterior pituitary. For instance, in birds, most of the somatotrophs are localized in the 
caudal lobe of the anterior pituitary, whereas corticotrophs largely appear in the cephalic 
lobe of the anterior pituitary (17).  
The development and differentiation of anterior pituitary cell types involves the 
pituitary-specific paired-like homeodomain factor prophet of Pit-1 (Prop-1) (18).  Prop-1 
is necessary for Pit-1 gene expression. Ames dwarf mice with a Prop-1 mutation do not 
express Pit-1, and consequently fail to produce Pit-1 lineage cell types (19). Pit-1 mutant 




Prop-1, in humans, is also believed to be required for the development of gonadotrophs 
(20).   
Factors that establish the different hormone-producing cell types during early 
anterior pituitary development are not entirely known. It is believed that the pattern and 
combination in which certain factors are expressed influence the expression of hormone-
producing genes, and in turn define the hormone-produing cell types (15, 21).  Studies on 
proopiomelanocortin (POMC; ACTH precursor),  have reported binding sites for several 
factors, including Nur77 (21). A number of other transcription factors like paired-like 
homeodomain 1 (Pitx-l), neurogenic differentiation 1 (NeuroD1), and T-box factor (Tpit) 
have been reported to be involved in transcription of the POMC gene. Tpit is specifically 
expressed only in corticotrophs and melanotrophs (α-MSH producing cells) (22). 
NeuroD1 is transiently expressed in fetal corticotrophs (23). GATA-binding protein-2 
(GATA-2) expression is found in both gonadotrophs and thyrotrophs. Gonadotroph 
development also requires steriodogenic factor 1(SF-1), early growth response-1(Egr-1), 
and Pitx1 (24). SF-1 is expressed prior to the onset of expression of the gonadotropin beta 
subunits. In gonadotrophs, GATA-2 expression together with SF-1, and importantly the 
absence of Pit-1 results in gonadotroph specific differentiation (25). On the other hand, in 
thyrotrophs, Pit-1 expression inhibits SF-1 expression, and GATA-2 and Pit-1 
combinatorial expression leads to TSHβ expression (26). Pit-1 expression is essential for 
three cell types: somatotrophs, thyrotrophs, and lactotrophs. The factors required for the 
terminal differentiation of these cell types are still not completely known. Pit-1 
interactions with additional factors, regulation of Pit-1 activity or differential expression 




Lactotroph restricted prolactin expression depends on Pit-1, v-ets erythroblastosis virus 
E26 oncogene homolog (Ets1), and Ptx factors (27). Besides Pit-1, somatotroph 
differentiation requires several other factors, including thyroid hormone (28) and Zn-15 
(29). In chickens, thyroid hormone treatement was shown to increase somatotrophs 
prematurely, and thyroid hormone synthesis inhibitor, methimazole, inhibited 
somatotroph differentiation in vivo, supporting the involvement of thyroid hormone 
synthesis in somatotroph differentiation (28). In rats, Zn-15 was identified to be involved 
in somatotroph differentiation. The rat GH promoter was thoroughly analyzed to identify 
a highly conserved sequence located between two Pit-1 sites. The importance of this site 
for GH expression was confirmed by mutational analysis. The factor binding to this site 
was subsequently identified by screening expression libraries from rat pituitary and was 
confirmed to be Zn-15 (29). 
Anterior pituitary somatotroph cells  
Somatotroph cells are responsible for GH synthesis and secretion. They are the 
most abundant cell type in the mature male pituitary (3, 30). They are acidophilic. They 
may be round, oval, or triangular. They have a large nucleus, well-developed Golgi 
complexes, granular endoplasmic reticulum, and large secretory granules. The number 
and size of somatotrophs and their secretory granules varies through ontogeny and 
maturation state (30)  
Somatotroph ontogeny 
 During rat embryogenesis, expression of GH mRNA is first noticeable around 




increase considerably between embryonic day (e) 18 and e19. During development in 
mice, GH mRNA is first detected on e15.5, and increases markedly between e16.5 and 
e17.5 (35, 36). In chickens, somatotrophs first emerge around e12, and like in rats and 
mice, the number of somatotrophs significantly increase between e14 and e16 during 
development (16, 17, 37-41).    
Growth hormone  
Anterior pituitary somatotrophs secrete GH in an episodic manner (30), and 
secretion varies during growth and maturation. GH is responsible for several 
physiological functions, including growth and metabolism. It increases protein synthesis, 
increases fat metabolism, and is involved in maintaining blood glucose level. GH 
deficiency in humans, especially children, results in growth defects, short stature, and 
decreased muscle mass (30, 42, 43). Excess GH leads to acromegaly or gigantism. GH 
secretion is tightly regulated by two hypothalamic factors: Growth Hormone Releasing 
Hormone (GHRH) and somatostatin. GHRH stimulates GH secretion, and somatostatin 
inhibits secretion (44). Upon secretion, GH binds to its receptor (GH-Receptor, GH-R) in 
the target tissues (liver, muscle), and activates signalling pathways (30). In liver, GH 
stimulates the Janus kinase-Signal Transducer and Activator of Transcription (JAK-
STAT) signalling pathway to produce insulin-like growth factor 1 (IGF-1) (45). IGF-1 
stimulates muscle and bone growth. IGF-1 exerts feedback inhibition on GH secretion 
through regulating hypothalamic factors (GHRH and somatostatin), GH and IGF-1 itself. 
In the hypothalamus, GH decreases GHRH mRNA and increases somatostatin mRNA, in 
turn decreasing GH secretion from the pituitary (43, 45). GH can also regulate GHRH 




release is also under negative regulation by thyroid hormones, which affect thyrotropin-
releasing hormone (TRH)-stimulated GH release (49, 50).   
Somatotroph differentiation and GH expression 
The chicken GH gene is about 3.5kb, and is present on the chromosome 27. It 
contains five exons, four introns, and 3‘ and 5‘ untranslated regions. The gene is similar 
in structure to other mammalian GH genes (51, 52). In humans, the GH gene produces 
two different mRNA products through alternative splicing at exon 3 (53, 54). In chickens, 
an alternatively spliced form of GH mRNA has only been reported in the eye, where a 
second GH mRNA is transcribed from the middle of intron 3 (55). Other than alternative 
splicing, GH protein can undergo post-translational modifications, including 
glycosylation and phosphorylation (30). GH gene abnormalities result in GH deficiency, 
which leads to dwarfism, as seen in GH deficiency type IA (56).  
GH gene transcription is regulated by cis-DNA elements that bind trans-acting 
regulatory factors (58, 59). Even though the chicken GH promoter sequence has few 
similarities with that of mammalian GH genes, it has binding sites for the essential 
factors, including Pit-1 (Fig 2) (60-62). It contains two putative Pit-1 binding sites at -
113/-104 (proximal site) and -541/-533 (distal site). Additionally, a potential Thyroid 
hormone response element (TRE) is also found at -137/-128. The TRE is hypothesized to 
mediate suppression of GH promoter activity by the thyroid hormone. There are two 








Figure 2. Schematic diagram of the GH gene in chickens. Shown are the putative binding 
sites for the pituitary-specific transcription factor Pit-1, TRE, and the TATA box within 
1800bp of the chicken GH gene. Figure taken from Leung, et al. (57). 
 
Pit-1 is essential but not sufficient for the complete activation of the GH gene 
promoter (61, 63). A mutation or absence of Pit-1 results in complete loss of functional 
somatotrophs. During development, Pit-1 expression precedes differentiation of 
somatotrophs (64). In rats, Pit-1 is first detected in the e15.5 pituitary, and in chickens, 
the mRNA for Pit-1 is first noted in e5 embryos (65, 66). Pit-1 binding sites are found on 
many genes, including GH, PRL, TSH, GHRH-receptor, and somatostatin receptor type 1 
(sst1) (3). In the human fetus, somatotroph differentiation and proliferation is stimulated 
by glucocorticoids and thyroid hormones (67-69), and is suppressed by insulin and 
glucogon (70). In the fetal rat, treatment with thyroid hormones also increases 
somatotroph proliferation, and this action requires the presence of glucocorticoids (71-
74). GHRH stimulates GH expression through binding to GHRH-R, and activates protein 
kinase A (PKA) signalling (75), which phosphorylates CREB-binding protein (CBP). Pit-




exposing the glucocorticoid and thyroid response elements. In humans, Pit-1 interacts 
with CBP, and histone acetyl transferase (HAT) activity of CBP allows activation of the 
GH promoter (76). 
 
Glucocorticoids 
Glucocorticoids are a class of steroid hormones (77). They are synthesized in the 
zona fasciculata cells of the adrenal cortex and released in a circadian manner. The 
primary glucocorticoid in humans is cortisol, while corticosterone (CORT) is the primary 
glucocorticoid found in many animals, including rodents and birds. Glucocorticoids have 
a wide range of functions. They stimulate gluconeogenesis by increasing expression of 
enzymes involved in gluconeogenesis, inhibit glucose uptake in muscle and fat tissues, 
and stimulate fat metabolism (77, 78). They suppress immune responses, and inhibit 
swelling and inflammation by regulating anti- and pro-inflammatory proteins. They also 
play important roles in fetal development. For instance, glucocorticoids are involved in 
the transcriptional regulation of surfactant protein A, a major protein required for proper 
development of the lungs (79, 80). Glucocorticoids are also referred to as the ―stress 
hormones‖ (78). Under stress conditions, the hypothalamus increases release of 
Corticotropin Releasing Hormone (CRH), which in turn increases ACTH secretion from 
the anterior pituitary. ACTH stimulates the synthesis of glucocorticoids in the adrenal 
cortex, eventually leading to increased glucose availability and increased blood flow.  
 Availability of glucocorticoids is maintained by two enzymes inside the cell: 11β-




converts active cortisol into inactive cortisone, and 11β-HSD1 converts cortisone into an 
active glucocorticoid (81). Corticosteroid binding globulin (CBG) or transcortin is the 
major glucocorticoid transport protein in the plasma (82). The free or unbound 
glucocorticoids, due to their hydrophobic nature, cannot pass freely across membranes. 
CBGs bind glucocorticoids reversibly. CBGs have high affinity and limited capacity for 
glucocorticoids (83, 84). It is not clear as to how CBG transports the glucocorticoids 
across cell membranes, but some reports suggest that CBG may be able to bind to 
different membranes. CBG also regulates the availability of glucocorticoids to the 
different tissues. Additionally, the amount of CBG available to bind to glucocorticoids is 
also regulated. A decrease in CBG level, increases levels of unbound cortisol, as in the 
case of Cushing‘s syndrome (85). Stress also decreases the half-life of CBG, which leads 
to increased free glucocorticoids. Long-term exposure to high levels of glucocorticoids 
causes damage to muscle tissues, increased blood pressure, diabetes, and weakens the 
immune system (78). 
Glucocorticoid receptor  
Glucocorticoids function through glucocorticoid receptor (GR). GR belongs to the 
nuclear hormone receptor superfamily and functions as a ligand-dependent transcription 
factor. Other members of this family of receptors include mineralocorticoid receptor 
(MR), androgen receptor (AR), and progesterone receptor (PR) (86) (87). GR is widely 
expressed in all tissues, including brain and pituitary, in both mammals and birds. 
Complete knockout of GR is lethal. Mice lacking GR die shortly after birth, due to 




Several isoforms of GR exist, the two main isoforms being GRα and GRβ (91, 
92).  The multiple isoforms of GR are generated by alternative splicing and alternative 
translation initiation (93-95). The full length GR has been cloned and sequenced for 
several species, including human, rat, mouse, and chickens (96-98).  
GR protein contains three major domains: an N-terminal transactivation domain 
(NTD), a central DNA-binding domain (DBD), and a C-terminal ligand-binding domain 
(LBD) (Fig 3) (87, 99). The DBD and LBD are separated by a hinge region. There are 
two nuclear localization signals (NLS) present, one in the hinge region and one in the 
LBD. The NTD contains transcriptional activation function (AF1), and activates gene 
transcription through interactions with different coregulators and the basal transcriptional 
machinery. The DBD contains two zinc-finger motifs that recognize specific DNA 
sequences on the target genes, and it binds DNA upon activation of the receptor through 
ligand binding. Additionally, GR also has a P-box that facilitates target site identification 
and a D-box that mediates receptor dimerization. The LBD binds the glucocorticoid, and 
contains an additional activation function (AF2) site. The LBD also binds chaperone 
proteins, such as heat shock protein 90 (hsp90) (Fig 3) (87, 100).  
 
Genomic actions of glucocorticoid receptor 
 Genomic actions of GR are a slow process, and occur within hours. In the 
absence of ligand, GR is found predominantly in the cytoplasm of cells. It resides in the 
cytoplasm as a multiprotein complex comprised of chaperone proteins (hsp90, hsp70), 











Figure 3. (A) Structural organization of glucocorticoid receptor, including the DNA 
binding domain (DBD) and ligand binding domain (LBD). Figure taken from Alberts, et 
al. (89). (B) Functioning of the glucocorticoid receptor. Upon hormone binding, the 
cytosolic nuclear receptor is activated, and translocated to the nucleus. In the nucleus, the 
activated receptor binds to the response element on the gene and activates gene 




facilitate in the proper folding of the GR protein and maintain GR in a transcriptionally 
inactive state. In the presence of glucocorticoids, GR undergoes a conformational change, 
which results in the dissociation of hsp90, hsp70 and FKBP (103). The NLS within the 
LBD is exposed and the glucocorticoid bound GR is translocated to the nucleus. The 
DBD of GR binds to target sequences on the DNA. Alternatively, GR can directly bind to 
other transcription factors to regulate gene expression (cis- or trans- regulation 
respectively) (Fig 4) (87, 105). The specific sequences on DNA that bind GR are called 
glucocorticoid-responsive elements (GRE) (105). GREs are typically found in the 
promoter region of a gene. GR binds GRE as a homodimer. A classical GRE sequence is 
an imperfect palindrome (GGTACAnnnTGTTCT) with two 6-bp half sites that are 
separated by a 3-bp spacer. GR can also effectively bind a GRE half-site and regulate 






Figure 4. Possible modes of action of GR. GR directly binds GRE on DNA (simple), or 
tethers to transcription factors that bind to transcription factor response element (TFREs) 
on DNA (tethered), or binds to DNA as well as interacts with transcription factors bound 




 GR can both activate and repress gene expression. In activating gene expression, 
DNA–bound GR interacts with ATP-dependent chromatin remodelling complexes 
SWItch/Sucrose NonFermentable (SWI/SNF), factors with histone acetyltransferase 
(HAT) activity like CBP and p300, and with the basal transcription machinery (108).  GR 
inhibits gene expression by binding to the so-called negative GRE (nGREs), and possibly 
by mediating the dissociation of positive transcription regulators.  
GR can also bind DNA in the form of heterodimers. It has been shown to 
heterodimerize with the STAT and Ets transcription factors and facilitate recruitment of 
coactivators or corepressors (109, 110). Coregulators play an essential role in GR-
dependent transcriptional regulation. It is important to understand that GR does not 
repress or activate a certain gene under all conditions. In addition, an activator may 
function as a repressor of the same gene in a context-dependent manner, and vice versa. 
Overall, the functioning of GR and its interacting partners is both gene and context 
dependent (109, 110). 
Glucocorticoid signalling is additionally regulated by post-translational 
modifications. GR can undergo several modifications, including phosphorylation and 
acetylation. Phosphorylation of GR promotes GR degradation, and regulates the 
translocation of liganded receptor from cytoplasm to nucleus (111-113). The human GR 
can be phosphorylated by several kinases, including MAPK and JNK. Five serine (S) 
residues in hGR may be phosphorylated by kinases: S113, S141, S203, S21, and S226. 
S203 and S211 phosphorylation by JNK leads to GR activation, while phosphorylation of 
S226 inhibits GR activity (111-113). Phosphorylation of S211 of GR increases its 




GR down-regulation occurs through ubiquitin-proteosomal degradation (114, 
115). The PEST motif located upstream of the DBD of GR has been identified as the 
ubiquitination site. Moreover, regulating the expression of an additional factor, E3 ligase 
carboxy terminus of Hsc70-interacting protein (CHIP) that is involved in the 
ubiquitination process, also has the ability to regulate GR signalling. Yet another 
important post-translational modification is the acetylation of GR at the conserved 
KXKK motif located near the NLS. GR can undergo both acetylation (by HATs) and 
deacetylation (by HDACs) (114, 115).  
As mentioned earlier, there are two isoforms of GR: GRα and GRβ. GRα can bind 
to glucocorticoids, whereas GRβ cannot (116, 117). Both GRα and GRβ bind DNA as 
either homodimers or heterodimers. GRβ is mainly found in the nucleus and functions 
independent of GRα (117). 
Nongenomic actions of glucocorticoid receptor 
The nongenomic actions of GR play important roles in many physiological 
processes, including immune and endocrine functions. These actions occur through 
alterations in membrane protein signalling, changes in cytoplasmic proteins like MAPKs 
and protein kinases that feed into different signalling pathways (118, 119). 
Glucocorticoid regulation of growth hormone gene expression  
Evidence for the involvement of glucocorticoids in GH gene regulation were 
based on intial studies using fetal rat pituitary cells taken at day 14, prior to the synthesis 




cortisol added were able to differentiate into GH cells, while no GH cells were found in 
the serum-free medium alone. Similar experiments conducted in chickens, using e10-e14 
pituitary cells cultured in the presence of serum from older birds (e12 or e16), pointed to 
the involvement of a blood-borne factor in initiating somatotroph differentiation (122-
124). The appearance of somatotrophs in rodents and chickens correlates with increased 
levels of glucocorticoids and thyroid hormone in the plasma, suggesting the possible 
participation of these factors in GH cell differentiation (120-122, 125, 126). 
Administration of ACTH caused a premature increase in GH cell numbers in chickens 
(127). Reducing the levels of endogenous glucocorticoids by the administration of 
metyrapone in pregnant rats resulted in significant reduction in the number of GH cells 
(128). Treatment with TSH, corticotropin-releasing hormone (CRH), α-melanocyte-
stimulating hormone (MSH), GHRH,
 
and TRH did not show similar effects.  
In situ hybridization, northern blot analysis and immunocytochemistry studies of 
dexamethasone (DEX; a synthetic glucocorticoid) treated rat pituitary cells, revealed an 
increase in GH mRNA and number of GH cells (120, 125, 126, 128-130). Similar results 
were also found in chickens, where CORT was able to induce premature differentiation 
of somatotroph cells both in vitro and in vivo (28, 39). CORT increased GH mRNA and 
protein levels, and importantly induced expression of GH mRNA in cells that did not 
express GH mRNA prior to the treatment. GH mRNA expression occurred within 8 h or 
3 h CORT treatment in rats and chickens, respectively (28, 39, 122, 125, 128, 129, 131, 
132). Also, in response to GHRH and TRH treatment, these cells released more GH, 
suggesting that the CORT-induced somatotrophs are functional (133). Thyroid hormone 




glucocorticoids (28, 122, 132). Similarly, using reverse hemolytic
 
plaque assays and 
immunocytochemistry in chickens, it was shown that thyroid
 
hormones can augment 
CORT effects but had little to no
 
effect on their own (34). Overall, there is sufficient 
evidence indicating the importance of glucocorticoids and thyroid hormone in GH gene 
induction, both in rodents and chickens. A working model was proposed summarizing the 
factors that may be involved in regulating GH expression in chickens (Fig 5). 
 
 
Figure 5. Representation of the factors affecting GH expression in the anterior pituitary. 
Hypothalamic factors along with glucocorticoids and thyroid hormones regulate the 
synthesis and secretion of GH from the somatotroph cells of the anterior pituitary. Figure 





Mechanism involved in glucocorticoid induction of GH gene transcription 
 The molecular mechanism involved in glucocorticoid induction of GH is still not 
completely understood. Studies in rodents and chickens have identified several 
independent aspects of regulation, but a lot remains unknown. Unlike the human GH 
gene, a classical GRE has not been found in the rat and chicken GH promoter, suggesting 
that GR may not necessarily bind to the DNA to mediate glucocorticoid effects (134). 
Glucocorticoid induction of GH gene expression is believed to be indirect and requires 
additional factors, both in rodents and chickens (135, 136). In fetal rat pituitaries, the 
dexamethasone-induced increase in GH mRNA levels was completely abolished in the 
presence of puromycin, a protein synthesis inhibitor (125). Similarly, pretreatment with 
cycloheximide (CHX), another protein synthesis inhibitor (135) attenuated the CORT-
induced increase in GH mRNA levels in chickens. CORT treatment, both in rats and 
chickens, did not affect Pit-1 mRNA or protein levels, suggesting that a change in Pit-1 is 
not the mechanism
 
underlying DEX-induced GH increase (135). Effects of CORT on 
GHRH-R were found to be species-specific. In fetal rats, CORT treatment increased 
GHRH-R mRNA levels, whereas in chickens, CORT had no affect on GHRH-R mRNA 
or protein levels (28, 46, 133, 137). Further, glucocorticoids may stimulate other types of 
pituitary cells to produce and secrete an unknown regulator, which, in turn may stimulate 
GH expression. Nevertheless, it can be concluded that CORT induction of GH gene 
expression requires an intermediary factor.  
 CORT can induce GH expression by binding to either GR or MR. GR expression 
is detected in the pituitary gland by e13 in mice and by e15 in rats (138). In mouse, MR is 




increase between e10 and e14 (139, 140). Evidence in rodents and chickens indicates that 
CORT regulation of GH requires GR and MR signalling (139). In chickens, blocking GR 
signalling alone by ZK98299, significantly reduced CORT-induced GH mRNA levels 
(141). Blocking MR alone with spironolactone had similar effects on CORT induction of 
GH mRNA. By blocking GR and MR together with both ZK98299 and spironolactone, 
CORT induction of GH mRNA was completely abolished.  
 CORT induction of GH gene expression does not seem to involve the two 
predominant GHRH-R signalling pathways – protein kinase C (PKC) and protein kinase 
A (PKA) pathways (133, 135). Neither activation nor inhibition of these pathways had 
any affect on the CORT-induced increase in GH mRNA levels. In contrast, inhibition of 
ras signalling by manumycin A suppressed CORT induction of GH mRNA, indicating 
the involvement of ras signalling or a ras-like factor in the process. Subsequently, using 
pharmacological inhibitors, it has also been determined that ERK1/2 may be the 
downstream ras effector required for GH induction by CORT (142).  
 As mentioned earlier, sequence analysis of human, rat and chicken GH gene 
reveals the presence of half-GRE sites, but no full length GREs. Leung and co-workers 
reported that a 1727bp sequence of the chicken GH promoter is responsive to 
dexamethasone treatment (60). In their experiment with rat pituitary cells, they showed 
that a reporter construct driven by a 1727bp sequence of the chicken GH promoter was 
able to activate luciferase expression in response to dexamethasone. Similar results were 
obtained in experiments conducted using chicken pituitary cells. E11 chicken pituitary 
cells were transfected with either pGL3-Basic empty vector or -1727/+48bp fragment 




a two-fold increased luciferase activity. Moreover, CORT induction of -1727/+48bp GH 
promoter requires ongoing protein synthesis and mimics the endogenous GH gene 
induction by CORT (141). Further characterization of the -1727/+47bp chicken GH 
promoter fragment by deletion mutation analysis revealed the presence of a 
glucocorticoid-responsive region (GCRR) between -1054 and -954. The GCRR can 
function both in forward and reverse orientations. Sequence analysis of  the GCRR 
fragment for putative transcription binding sites revealed the presence of binding sites for 
several factors, including Ets1(141). Further, binding of Ets1 and GR to the GCRR was 
also confirmed by electrophoretic mobility shift assay (EMSA). Further support for the 
importance of the Ets1 and GRE half-site within the GCRR site for CORT induction of 
the GH gene came from site-directed mutation studies, wherein mutation of these sites 
abolished CORT responsiveness (141). 
 
Histone Modifications 
The main subunit of chromatin is the nucleosome. The nucleosome contains 
~200bp of DNA coiled around a protein core called histone. The histone (H) core is an 
octamer that consists of two copies each of H2A, H2B, H3 and H4 (143). Series of 
nucleosomes are tightly packed into chromosomes. The less densely packed regions of 
the chromatin are called euchromatin, whereas the tightly packed regions are known as 
heterochromatin. Each core histone is made of a central protein and a flexible N-terminal 
tail. The N-terminal tail sequences are highly conserved and are important in regulating 




modifications. The patterns of modifications (sometimes referred to as a histone code) are 
suggestive of a particular read-out and lead to a certain biological outcome (143, 145). 
Overall, the patterns of histone modifications influence transcription initiation by 
regulating chromatin accessibility.  
Types of histone modifications 
Histones can undergo several covalent modifications, including acetylation, 
methylation and phosphorylation (Fig 6) (145). Each of these modifications is carried out 
by specific enzymes and can be reversed by a set of specific enzyme. Acetylation was the 
first identified post-translational modification of histone (145, 146). It is catalyzed by 
histone acetyltransferases (HATs), which add an acetyl group to the amino side chains of 
lysine residues (147). Several lysine residues have been identified as acetylation targets, 
including lysine 9, 14, 18, and 23 on H3. Acetylation by HATs results in the reduced 
affinity between histones and DNA, and this consequently leads to a more open 
chromatin that allows the RNA polymerase II and transcription factors to access the 
promoter region. A highly active gene is usually marked by high levels of histone 
acetylation (146, 148). Acetylation is reversed (deacetylation) by histone deacetylases 
(HDACs). HDACs remove the acetyl groups and support gene repression through closed 
chromatin conformation (147-150). HATs are considered transcriptional coactivators, 
while HDACs are referred to as corepressors. HATs and HDACs are recruited as a part of 
a larger complex, and in response to specific biological stimulations, they either induce or 
suppress gene expression. A second kind of modification is histone methylation, and this 











Figure 6. (A) The nucleosome with the histone proteins. A schematic representation of 
histone modifications involved in regulation of gene transcription. (B) Effect of histone 
acetylation and DNA methylation on remodelling chromatin structure. The repressed 
closed state is deacetylated. Acetylation of histone as well as DNA demethylation imparts 
an open chromatin structure facilitating activation of gene transcription. Figure taken 




addition of one, two, or three methyl groups (mono, di, or trimethylated, respectively) to 
lysine or arginine residues in histones (145, 151). The effect of methylation on gene 
transcription depends on which lysine residue is modified, as well as the type of 
methylation (number of methyl groups added). Mono-methylation of lysine 4, 9 or 27 is 
associated with gene activation, di-methylation is linked to repression, tri-methylation of 
lysine 4 (H3me3K4) is linked to gene activation, and tri-methylation of lysine 9 or 27 
(H3me3K9 or K27) is related to gene repression (145, 151-155). 
Histones can be phosphorylated at selected serine and threonine residues. Of all 
the histones, Histone H1 is the most phosphorylated. Although the role of H1 
phosphorylation remains elusive, it is hypothesized that it plays an important role in 
formation of higher-order chromatin structures (156, 157). Histone H3 phosphorylation 
occurs on serine residues. H3 phosphorylation of serine 10 (H3S10) is widespread in cells 
entering mitosis and in cells stimulated by growth factors. Interestingly, increased H3S10 
phosphorylation occurs in genes activated by growth factors (156). Kinases responsible 
for histone phosphorylation are not well known. Other than acetylation, methylation, and 
phosphorylation, histones can be modified by attachment of ADP-ribose moieties or 
ubiquitinated (156-159). 
 Apart from the above-mentioned covalent modifications of histones (by HATs, 
HDACs, and HMTs), non-covalent modifications also play important roles in gene 
transcription. The non-covalent modifications are introduced by chromatin remodelling 
complexes that utilize ATP to bring about changes in the chromatin (160). All the ATP-
dependent chromatin-remodelling complexes have an ATPase subunit. Most of the well- 




the Snf2 deacetylase (160, 162). The mechanism of action of ATP-dependent 
remodelling complexes is not well known. In general, it involves recruitment of these 
factors to the DNA-nucleosome, followed by ATP-dependent disruption or alteration of 
nucleosome structure. Interestingly, it was found that HATs and HDACs associate with 
remodelling complexes and seem to work in concert to regulate gene transcription (159, 
160, 162-165). 
Effects of glucocorticoids on histone modifications 
Histone acetylation by HATs relaxes the DNA and gives chromatin a configuration that 
allows access to transcription factors, and thus acetylation is linked to transcriptional 
activation. Some coactivator proteins have intrinsic HAT activity, for example, p300 and 
CBP (108). CBP and p300 are known GR interacting proteins (Fig 7) (108, 166, 167). 
Interaction of ligand-bound GR with HATs, including CBP and p300 plays an important 
role in transcription of glucocorticoid-regulated genes. GR has also been shown to 
interact with other HAT activity-containing proteins like steroid receptor coactivator-1 
(SRC-1) and glucocorticoid receptor-interacting protein 1(GRIP-1) (167-169). It is 
known that glucocorticoid-mediated histone modifications play important roles in gene 
regulation. Glucocorticoids inhibit expression of surfactant protein A (SP-A) through the 
recruitment of HDACs in the human lungs (79, 170, 171). Glucocorticoids also regulate 
H3 phosphorylation and methylation of histones associated with SP-A gene. In mice, 










Figure 7. Model representation of factors involved in nuclear receptor-mediated gene 
transcription. Upon activation, the GR binds to the GREs on the target gene. GR 
interaction with chromatin remodellers (SWI/SNF) and histone modifiers (p300/CBP) 
helps chromatin attain a more favorable conformation that facilitates the binding of basal 
transcription machinery leading to gene activation. Figure taken from Charmandari, et al. 









Epigenetic regulation associated with GH gene expression 
Pituitary development and cell-lineage determination involve epigenetic 
modifications of chromatin. Histone lysine demethylase LSD1 is part of a multiprotein 
corepressor complex, and LSD1 has been shown to be important for the differentiation of 
somatotroph cells during pituitary development (1, 172). Pituitary-specific knockout of 
LSD1 in mice resulted in a complete loss of GH and TSH cells (1). In the LSD1 knockout 
mice, recruitment of Pit-1 to the GH promoter was not affected. Furthermore, co-
immunoprecipitation experiments showed interaction between LSD1 and Pit-1, strongly 
suggesting the requirement of histone modifications in GH gene expression (1, 172-174). 
Moreover, the expression of Zinc finger E-box-binding homeobox 1 (ZEB1) repressor in 
lactotroph cells suppresses expression of the GH gene, and ZEB1 was shown to interact 
with LSD1 as part of a large repressor complex (Fig 8). Taken together, there is clear 
evidence for involvement of histone modifications in both activation and repression of 
the GH gene (174). 
 
 
Dexamethasone-Induced Ras1 (Dexras1) 
In addition to studies on epigenetic effects, the current research assessed the regulation 
and role of Dexras1 in controlling pituitary GH expression. Dexamethasone-induced Ras 
protein1 (Dexras1) is a member of the Ras superfamily of monomeric G proteins. It is a 
GTP–binding protein. The Dexras1 gene in chickens is located on chromosome 14. It 
contains two exons and is 1638bp in length. The chicken Dexras1 cDNA was isolated 







































































































































































































































































































The library was generated from the hypothalamus, anterior pituitary gland, and pineal 
gland of chickens ranging in age from e12 to d3. The Dexras1 cDNA clone has an 837bp 
open reading frame and encodes for a 278 amino acid protein (176). The predicted 
Dexras1 protein has a molecular mass of approximately 31.5 kDa. Dexras1 has also been 
isolated from other species including rat, mouse, and human (177-181). The human 
homolog of Dexras1 is also referred to as the activator of G-protein signalling-1 (AGS-1).  
Dexras1 was first identified in the AtT-20 murine corticotroph cell line (177). In 
these cells, glucocorticoid treatment significantly stimulated Dexras1 mRNA expression, 
and this characterized Dexras1 as a novel glucocorticoid-target gene (177, 182). Dexras1 
is highly conserved among species. The human and mouse isoforms share approximately 
98% protein homology. Chicken Dexras1 is 85% similar to that of its rat and human 
orthologs. Chicken Dexras1 has characteristic features of proteins belonging to the ras 
superfamily (176). It contains all the important conserved domains and motifs that are 
required for ras functions like the guanine nucleotide-binding motif, the C-terminal 
membrane targeting farnesylation CAAX site, the P-loop, and the EXSAK site (183, 
184). 
 
Ras proteins and ras signalling pathway  
Ras proteins function as important molecular switches that regulate cytoplasmic 
signalling networks. Their activity depends on binding to either GTP or GDP (184). The 
GTP-bound ras state is considered as ―active‖ or ―ON‖, while the GDP-bound state is 




protein undergoes conformational changes depending on whether a GTP or a GDP 
molecule is associated with the ras protein. Ras proteins have low intrinsic GTP 
hydrolysis and GTP/GDP exchange capabilities, and they require additional regulatory 
factors for proper functioning. GEFs (guanine nucleotide exchange factors) function as 
positive regulators, while GAPs (GTPase activating proteins) act as negative regulators 
(Fig 9). GEFs promote dissociation of GDP and the binding of GTP. GAPs, on the other 
hand, increase GTP hydrolysis and stimulate formation of inactive GDP-bound ras. The 
GTP-bound conformation of ras proteins presents a favorable interaction with GAPs, 





Figure 9. The Ras protein, a small G protein can bind GDP or GTP. Shown here are the 
two forms of ras protein. GTP-bound form is regarded as the active form, while the GDP-
bound ras protein is the inactive form. The GEFs and GAPs are the positive and negative 





conditions there is an excess of GTP in the cell. Consequently, it has been found that any 
mutation within the ras gene that causes a decrease in the affinity for guanine nucleotides 
produces a constitutively active phenotype. A single nucleotide substitute mutation in the 
G4 domain of the Dexras1 guanine nucleotide-binding pocket (A178V) was shown to 
have an increased Dexras1 function (180, 182, 187, 188). The mutant had lowered 
affinity to GTP than the wild type in vitro. In contrast, in vivo studies showed the 
opposite, where the mutant Dexras1A178V bound to twice as much GTP as wild type 
protein (188). Upon activation, ras proteins interact with several downstream effectors 
leading to control of gene expression, cell proliferation, differentiation, and apoptosis 
(178, 182, 187, 189). Some of the well-known ras effector molecules include Raf, 
phosphatidylinositol 3-kinase (PI3-K), and phospholipase-C (PLCε). Raf phosphorylation 
leads to activation of MAPK pathways and phosphorylation of ERK (Fig 10) (190). 
Activated ERK translocates to the nucleus and phosphorylates Ets-family transcription 
factors (Elk-1). The ras pathways are complex networks of proteins and present an even 
more complicated regulatory network. Ras proteins can also be regulated through 
modifications such as phosphorylation and acetylation (191).  
  Ras proteins are synthesized as cytosolic precursors with a CAAX motif at the 
carboxy-terminal (191). The CAAX motif undergoes enzymatic post-translational 
modification (prenylation or farnesylation), which promotes the translocation of the ras 
protein to the plasma membrane. The covalent modification is critical for ras membrane 
association. There are contradicting views about whether all ras proteins need to be 







Figure 10. Activation of ras protein and ras signalling pathway. Extracellular stimuli lead 
to receptor activation, which leads to the activation of ras proteins positioned close to the 
receptor. Ras proteins are attached to the membrane. Ras signalling activation could then 
activate any one of the above-mentioned pathways and effect several different functions. 
Figure taken from Perentesis, et al. (186).   
 
 
association is a limiting factor for the proper function, and disruption of translocation or 
farnesylation by pharmacological inhibitors like manumycin or mutation to the CAAX 
domain has been shown to abrogate ras signalling (178, 190-192). Ras signalling and 




Reports in mammalian cells show that the βγ subunits of heterotrimeric G proteins 
connect GPCRs with the MAPK pathways through small GTP-binding proteins (194). 
Functions of Dexras1 
Dexras1 mRNA is rapidly induced by glucocorticoids in a dose-dependent 
manner in AtT-20 cells (177). The amount of time required for glucocorticoid induction 
of Dexras1 was consistent with the time required for glucocorticoid inhibition of 
stimulated ACTH secretion, suggesting that Dexras1 may be involved in the 
glucocorticoid-mediated negative feedback inhibition in the corticotrophs cells (177, 192, 
195). The role of Dexras1 in ACTH secretion from pituitary cells remains to be 
confirmed. In the same study, it was also demonstrated that Dexras1 could regulate 
cAMP-stimulated secretion of co-transfected hGH (180). In AtT-20 corticotroph cells 
and COS-7 fibroblast cells, the expression of a constitutively active Dexras1 mutant 
(Dexras1A1788V) decreased the cAMP-stimulated secretion of transfected hGH by 86% 
(192).  The inhibition was reversed when a CAAX-mutant Dexras1 was transfected, 
suggesting the need for prenylation in this function. The significance and mechanism 
underlying this decreased GH secretion is not yet clear. Nevertheless, this study does 
raise a possible role of Dexras1 in secretory or endocrine functions. 
In mouse pituitary cells, Dexras1 expression can be stimulated by glucocorticoids, 
thyroid hormone, and 17-estradiol (E2) (196, 197). The fact that Dexras1 can be 
regulated by multiple factors in pituitary cells also points to the possibility that Dexras1 
may be expressed in more than one pituitary cell type. Additionally, Dexras1 may have 




Recent investigations show that Dexras1 has distinct roles in a ligand-independent 
and ligand-dependent manner (187, 189, 190, 193). An important feature in both cases is 
that Dexras1 seems to communicate between Gi-mediated signal transduction and the 
ERK-1/2 MAP kinase pathway  (190). In the absence of receptor activation (ligand-
independent), Dexras1 favors the GTP-bound state of Giα, which stimulates the 
dissociation of Gβγ. This results in increased Gβγ-dependent activation of the 
Ras/Raf/MEK/ERK cascade, which leads to an increase in Elk-1 transactivation (187, 
190, 194). On the other hand, in the case of ligand-dependent receptor activation, 
Dexras1 interferes with receptor activation of Gi by interfering with the ADP-ribosylation 
of Giα (188, 189, 193, 198, 199). Although, it is not completely clear as to how Dexras1 
selectively differentiates between the two scenarios. Dexras1 has also been shown to 
block Gβγ-regulated inwardly rectifying K+ channel (GIRK), possibly by interfering with 
GPCR signalling (200). In addition, Dexras1 has also been found to negatively modulate 
adenylate cyclase 2 (AC2) signalling indirectly through the inhibition of both Gβγ- and 
PKC-stimulated AC2 activity (188). Further, Dexras1 has been implicated in the 
maintenance of the circadian clock through integration of photic/nonphotic inputs (201). 
Dexras1 was shown to affect the photic sensitivity of mice. Behavioral studies conducted 
using Dexras1 knockout mice (Dexras1
-/-
) showed that Dexras1
-/- 
mice have lowered 
responses to photic stimuli and enhanced responses to nonphotic stimuli. Phosphorylated 
ERK (p-ERK) levels were compared between wild type and mutant mice after both dark 
and light stimuli (86, 202-204). Light-induced p-ERK expression was significantly 
attenuated in the Dexras1
-/-
 mice, indicating that Dexras1 is modulating the response to 




pathway. Further, this role of Dexras1 was shown to involve the N-Methyl-D-aspartic 
acid (NMDA) receptor (205, 206). Other studies have shown that Dexras1 can be 
activated by the NMDA receptor, which ultimately leads to MAPK activation.  
In the primary cortical neurons of mice, activation of Dexras1 by NMDA 
receptors results in increased iron uptake. In these cells, Dexras1 regulates iron import 
transporter, divalent metal ion transporter 1 (DMT1), through its interaction with the 
peripheral benzodiazepine receptor-associated protein (PAP7) (205).  
An interesting novel function of Dexras1 as a suppressor of gene transcription 
was reported in FE65- gamma-secretase-derived amyloid precursor protein (APP)-
mediated transcription (207). Dexras1 was shown to be able to bind to the PTB2 domain 
of FE65 protein and suppresses transcription. Importantly, this study revealed that 
Dexras1 may also be found in the nucleus, and may be able to interact with other 
transcription factors to regulate gene transcription.  
Other than the fact that glucocorticoids and estradiol regulate Dexras1 expression, 
the mechanism, and molecular details of Dexras1 regulation have not received much 
attention. A recent study reported that Dexras1 can also be induced by amphetamine 
(psychostimulant) in the rat prefrontal cortex, and that D2 dopamine and glucocorticoid 
receptors regulate these effects (208). The Dexras1 gene can also be silenced through 
DNA methylation (209). Such an epigenetic inactivation has been suggested to play an 
important role in the development of glucocorticoid-resistance, especially in the case of 




Chicken Dexras1: Ontogeny and tissue distribution  
The major sites of Dexras1 expression in human and mice include heart, brain, 
placenta, lung, liver, skeletal muscle, kidney, and pancreas (180). Interestingly, Dexras1 
expression was found to be limited to the pituitary tissues of 3-weeks-old juvenile 
chickens (176). Northern blot analysis on other tissues including brain, liver, lung, and 
pancreas did not reveal Dexras1 expression. Indeed, this does not rule out the possibility 
that Dexras1 may be expressed in other tissues at a later stage in development or in adult 
chickens.   
Ontogenic profile of Dexras1 expression in the anterior pituitary during 
development in chicken embryos was determined by microarray and qRT-PCR. Dexras1 
expression was detectable at e10 and increased between e12 and e17(142, 176). Dexras1 
expression in earlier developmental stages has not been tested. The increase in Dexras1 
expression was correlated with an increase in serum CORT levels as well as GH 
expression in the anterior pituitary(140, 176).  
.  
Rationale and Objectives 
Glucocorticoids (such as CORT) are involved in GH expression, and glucocorticoid- 
mediated GH expression is achieved through the combined effects of genomic and non-
genomic factors. CORT induction of GH mRNA expression in chickens requires ongoing 
protein synthesis, suggesting the involvement of unknown intermediary factor(s). 
Additionally, ras signalling is essential for CORT-mediated GH mRNA expression. The 




of these unknown intermediary factors are conceivably ras-like factors, or relay signals 
through the ras pathway. Dexras1, a ras-protein, exhibits a similar expression profile to 
that of CORT and GH during anterior pituitary development in chickens. Importantly, 
Dexras1 is a CORT-induced factor, and in e11 cultured chicken pituitary cells, the time 
required for CORT induction of Dexras1 is comparable to that of CORT induction of 
GH. Both inductions occur within 3 h of CORT treatment. These facts taken together 
suggest that Dexras1 could be the unknown CORT-induced factor that mediates CORT 
effects on GH expression. In addition to the involvement of CORT-induced intermediary 
factors, GH mRNA expression is also known to involve epigenetic modifications and 
recruitment of important transcription factors to the GH promoter. Previous studies have 
never addressed the effect of CORT on epigenetic modifications and transcription factor 
recruitment associated with the GH promoter. Towards a better understanding of 
molecular mechanisms involved in CORT induction of GH mRNA, including both 
genomic and non-genomic factors, the following objectives were addressed in this study. 
A) Characterization of glucocorticoid regulation of Dexras1 
- Role of GR and MR. 
- Role of intracellular cell signalling pathways involved.  
- Identification of Dexras1 expression in anterior pituitary cell types 
- Effect of CORT on subcellular localization of Dexras1  
B) Role of Dexras1 in regulating CORT-induced GH expression   
- Effect of overexpression of Dexras1 on GH promoter activity 
- Effect of overexpression of Dexras1 on GH mRNA expression  




D) Effect of CORT on histone H3 acetylation, trimethylation of lysine 4, and 
trimethylation of lysine 27 
E) Effect of CORT on recruitment of GR, Ets-1, and Pit1 to the GH promoter 



































Glucocorticoid-regulated histone modifications, and recruitment of GR, 













Epigenetic regulation by glucocorticoids through histone modifications plays an 
important role in gene expression. However, glucocorticoid-regulated modifications of 
histones associated with the growth hormone (GH) gene remain unknown. In chickens 
and rodents, glucocorticoids (e.g. corticosterone; CORT) induce GH mRNA expression 
in the anterior pituitary during embryonic development. 1727bp of the 5‘-flanking 
sequence of the chicken GH gene are sufficient for CORT induction of GH promoter 
activity. The 1727bp region contains two predicted Pit-1 sites, a glucocorticoid-
responsive region (GCRR), and other putative transcription factor binding sites. Using 
chicken embryonic pituitary cells, we tested the effect of CORT (1.5 h or 6 h) on histone 
H3 modifications, RNA Polymerase II (Pol II) recruitment, binding of the glucocorticoid 
receptor (GR) and transcription factors Pit-1 and Ets1 to the 5‘-flanking region of the GH 
gene, using chromatin immunoprecipitation (ChIP) assays followed by quantitative real 
time PCR. We found increased H3 acetylation and tri-methylation of lysine 4 at both Pit-
1 sites and the TSS (transcription start site) in response to 1.5 h CORT treatment. Furthermore, 
1.5 h CORT treatment significantly increased recruitment of Pit-1 and Pol II to the 
proximal Pit-1 site and the TSS, respectively. GR was recruited to the GCRR and the 
distal Pit-1 site in response to 1.5 h CORT treatment, while 6 h CORT treatment resulted 
in Ets1 dissociation from the GCRR. Collectively, these results indicate that CORT 
results in dynamic changes in histone modifications and transcription factor recruitment 







Pituitary growth hormone (GH) expression in chickens can be prematurely 
stimulated by the adrenal glucocorticoid, corticosterone (CORT). GH expression 
normally appears around embryonic day (e) 12 in chickens, but e11 chicken pituitary 
cells treated with CORT show an increase in GH mRNA and protein levels both in vivo 
and in vitro (210). In addition, in rodents as well as in chickens, the glucocorticoid-
mediated increase in GH gene expression is an indirect effect and involves additional 
factors (125, 135). Indeed, a role for CORT in regulating GH gene expression in pituitary 
cells is well established in rodents and chickens (28, 73, 125, 133, 211, 212). Most of the 
work on glucocorticoid regulation of GH gene transcription has focused on the 
involvement of transcription factors such as Pit-1 and glucocorticoid receptor (GR). In 
addition to the transcription factors, the MAPK/ERK pathway is also essential (142). GH 
expression in mice is known to involve epigenetic modifications (1, 213). However, the 
function of histone modifications in CORT-mediated GH gene expression is essentially 
unknown. There have been reports presenting the importance of glucocorticoid-induced 
histone modifications in regulation of other genes. For example, glucocorticoids inhibit 
expression of surfactant protein A (SP-A) through the recruitment of histone deacetylases 
(HDACs) in the human lung (79). Glucocorticoids also regulate H3 phosphorylation and 
methylation of histones associated with the SP-A gene (80, 170). In mice, glucocorticoids 
induce H3 acetylation on the β-casein gene (214). In mice, lysine-specific demethylase-1 
(LSD1) is essential for pituitary somatotroph and thyrotroph differentiation (1). 
Successful expression of GH and thyroid-stimulating hormone β (TSHβ) depends on the 




somatotrophs and thyrotrophs in mice. Although loss of LSD1 did not inhibit Pit-1 
recruitment to the GH promoter in these mice, LSD1 was shown to interact with Pit-1, 
establishing a connection between histone demethylation and pituitary-specific GH 
expression (1, 174). Moreover, suppression of GH expression in lactotrophs depends on 
an additional repressor, zinc finger E-box binding homeobox 1 (ZEB1). Interestingly, 
ZEB1 is known to interact with LSD1 as a part of a repressor complex in the REST 
(RE1-silencing transcription factor) gene. The role of glucocorticoids in the epigenetic 
regulation of GH expression was not addressed in this previous study (1).  
The main aim of the present study was to determine whether CORT induces 
histone modifications at the GH promoter. We hypothesized that gene-activating histone 
modifications, specifically histone H3 acetylation and tri-methylation of lysine 4, are 
stimulated at the GH promoter by CORT. We further hypothesized that these 
modifications in response to glucocorticoids are associated with recruitment of additional 
transcription factors. Pit-1 is known to be essential for GH expression. In addition to Pit-
1, we also investigated recruitment of GR and v-ets erythroblastosis virus E26 oncogene 
homolog 1 (Ets1) to the GH promoter by CORT. A 1727bp sequence of the chicken GH 
promoter has been shown to be responsive to CORT in e11 chicken pituitary cells (60, 
141). E11 chicken pituitary cells transfected with -1727/+48bp of the GH promoter 
showed five-fold increased luciferase activity of the reporter construct in response to 
CORT (141). Moreover, CORT induction of -1727/+48bp GH promoter also required 
ongoing protein synthesis, thereby mimicking induction of the endogenous GH gene by 
CORT (141). The 1727bp sequence was subsequently characterized and shown to contain 




element (GRE) half-site, and an Ets1 binding site (60, 141). The proximal Pit-1 site has 
been identified to be important in the expression of GH (60). The GCRR and its Ets1 and 
GR-binding sites were shown to be important for CORT-responsiveness of the reporter 
through mutational analysis (141).  
 Using ChIP on e11 embryonic chicken pituitary cells, we provide evidence for 
glucocorticoid regulation of GH gene expression through histone modifications and 
transcription factor recruitment. Specifically, we have identified sites on the GH 
promoter that undergo histone H3 acetylation and tri-methylation of lysine 4, both of 
which are accepted markers of gene activation. We also describe occupancy and 
recruitment of RNA Pol II, GR, Pit-1, and Ets1 to the different elements in a CORT-
dependent manner. Overall, we provide a detailed understanding of both temporal and 
spatial changes in histone modifications and transcription factor recruitment that occur on 
the GH promoter in response to CORT. 
 
Materials and Methods 
Reagents and antibodies 
Cell culture media were purchased from Invitrogen (Carlsbad, CA). 
Corticosterone was obtained from Sigma Chemical Company (St. Louis, MO). 
Antibodies used were as follows: acetylated H3 (Millipore #06-599), tri-methylated H3 
lysine 4 (Abcam #ab8580), tri-methylation lysine 27 (Abcam #ab6002), RNA Pol II 
(Santa Cruz Biotechnology #sc-899), Pit-1 (rabbit anti-rat Pit-1 antiserum previously 




GR) (98), Ets1 (Santa Cruz Biotechnology #sc-112), total H3 (Active Motif #39163), and 
normal rabbit serum (Calbiochem #869019).  
Chicken pituitary dissection and dispersion 
All chicken embryo protocols were approved by the Institutional Animal Care and 
Use Committee on the campus. Broiler chicken fertilized eggs were incubated in a 60% 
humidified, 37 C incubator. The first day of incubation was marked as embryonic day (e) 
0. Pituitaries were dissected from e11 chicken embryos under a light microscope. An e11 
chicken pituitary yields approximately 300,000 cells. Approximately 220 e11 pituitary 
glands were isolated for each replicate experiment. Anterior pituitary tissues were trypsin 
digested to obtain a single cell suspension as previously described (39). Cells were 
counted using the trypan blue exclusion method, and the viability rate was above 95% in 
all experiments.  
Cell culture and chromatin preparation 
 Approximately 5 x 10
6
 e11 pituitary cells per immunoprecipitation were used. 
Cells were resuspended in DMEM/F12 cell culture medium with supplements of 0.1% 
BSA (bovine serum albumen), 100
 
U/ml penicillin, and 5µg/ml human insulin and plated 
in 100mm x 20mm Corning
®
 cell culture petri dishes. Cells were plated on three petri 
dishes, one for each time point. Each petri dish containing cells was resuspended in 6ml 
of culture medimlum and maintained at 37 C. The cells were allowed to recover 
overnight, and the cells were then treated with either vehicle (0 h) or CORT (1nM) for 
1.5 h or 6 h. Following treatment, 200µl of 37% formaldehyde was added drop-wise 




room temperature. Next, 625µl of 1M glycine was added for 5 min to quench the 
formaldehyde. The petri dishes were then transferred to ice, and the cells were scraped 
into 50ml conical tubes. The petri dishes were washed twice with 2ml of ice-cold PBS 
containing 1mM phenylmethylsulfonyl fluoride (PMSF) and 1X Halt Protease Inhibitor 
Cocktail (Thermo Scientific). The cells were collected at 3000xg, and the pellet was 
washed once with PBS containing 1mM PMSF. The cells were resuspended in swelling 
buffer [25mM Hepes pH 7.8, 1.5mM MgCl2, 10mM KCl, 0.1% NP-40, 1mM 
dithiothreitol (DTT), 0.5mM PMSF, and 1x Halt Protease Inhibitor Cocktail 
(Thermoscientific, Rockford, IL)] and incubated on ice for 10 min. The cell suspension 
was homogenized with a Dounce homogenizer with 15 up and down strokes using a loose 
fitting pestle. The preparations were transferred to 15ml conical tubes and centrifuged at 
1800xg for 5 min. The nuclear pellets were resuspended in 2ml of Mononuclease 
(MNase) Buffer (0.32 M sucrose, 50mM Tris-HCl pH 7.4, 4mM MgCl2, 1mM CaCl2, 
0.1mM PMSF, 1% sodium dodecyl sulfate (SDS)) and homogenized with a Polytron PT 
1200C (Kinematica, Bohemia, NY) for 30 s on ice. A small volume (15µl) of the 
preparation was removed at this time and stored as the ―non-sheared control‖. Next, 10µl 
of BSA and 7.5µl of mononuclease (MNase) enzyme (New England Bio Labs, Ipswich, 
MA) were added to each sample and incubated at 37 C for 15 min, with tubes inverted 
every 5 min. 100µl of 0.5M ethylenediaminetetraacetic acid (EDTA) were added to stop 
the reaction. At this stage, the samples were stored overnight at -80 C. The samples were 
then sonicated using a Branson Sonifier 250. The tubes were placed in an ice-ethanol 
bath to keep the samples cold during sonication. Sonication settings were as follows: 5 




After sonication, the samples were centrifuged at 14,000xg at 4 C for 10 min, and the 
supernatants were transferred to fresh tubes. Shearing (500-700 bp fragments) was 
confirmed by seperating a small amount of each sample in an agarose gel. Chromatin was 
quantified using Quant-it Picogreen DNA Quantification Kit (Invitrogen, Carlsbad, CA). 
The quantified chromatin was aliquoted and stored at -80 C. 
Chromatin immunoprecipitation 
Sheared chromatin (10µg) was pre-cleared twice for a total of 24 h at 4 C with 
rotation with prewashed protein G magnetic beads (New England Bio Labs, Ipswich, 
MA) and 0.25mg/ml normal rabbit serum. The pre-cleared chromatin was transferred to 
new tubes and incubated overnight at 4 C with appropriate antibodies. Before addition of 
antibody, a control aliquot (2% input) was removed. Remaining samples were incubated 
at 4C overnight with antibodies against total H3, acetyl H3, tri-methyl H3 lysine 4, tri-
methyl H3 lysine 27, RNA Pol II, Pit-1, GR, Ets1 or normal rabbit serum (NRS). 2µg of 
each antibody was incubated with 10µg of pre-cleared chromatin in a 750µl reaction 
volume. Complexes were precipitated by incubating samples with protein G magnetic 
beads (New England Biolabs, Ipswich, MA) for 5 h at 4 C with rotation. The beads were 
washed 2x each with low salt wash buffer (50mM Hepes pH 7.9, 140mM NaCl, 1mM 
EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS, 0.5mM PMSF, 1x Protease 
Inhibitor Cocktail), high salt wash buffer (50mM Hepes pH 7.9, 500mM NaCl, 1mM 
EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS, 0.5mM PMSF, 1x Protease 
Inhibitor Cocktail), lithium chloride (LiCl) wash buffer (20mM Tris pH 8.0, 1mM 
EDTA, 250mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate, 0.5mM PMSF, 1x Protease 




The immunoprecipitated chromatin was eluted from the beads with elution buffer (50mM 
Tris pH 8.0, 1mM EDTA, 1% SDS, 50mM NaHCO3) at 65 C with rotation for 30 min. 
The supernatant was transferred to new tubes containing 15µl of 5M NaCl and 25ng 
RNaseA and incubated at 37 C for 30 min to reverse crosslinking. Next, 250ng of 
Proteinase K (Sigma Aldrich, St. Louis, MO) was added, and the samples were incubated 
at 65 C with rotation overnight. Samples were purified using the Wizard SV PCR clean 
up kit according to the manufacturer‘s instructions (Promega, Madison, WI) with the 
following modification: the final product was eluted twice with 40µl of water. 
Quantitative real time PCR (qPCR) 
 Real time PCR was performed in 96-well plates on a Bio-Rad iCycler. The 
following reaction mixture was used: 0.1% Triton X-100, 10mM Tris–HCl, 50mM KCl, 
1.9mM MgCl2, 2U Taq, 10mM each dNTP, 80nM each primer, 20nM fluorescein, and 
SYBRgreen II. 5ul of each cleaned immunoprecipitated DNA or input sample was used 
in 30µl reactions in duplicates. A list of primers used is given in Table 1. A three-step 
qPCR with the following reaction conditions was used: 40 cycles of 95 C for 15 s, 60 C 
for 30 s, and 72 C for 30 s. Data are presented as percentage of input. For each sample, a 
NRS antibody control Ct value was subtracted
 
from the sample Ct value to account for 
general background. The Ct values were transformed (2
Ct
), and the sample Ct values 





Data presented are the means of three to six independent replicates. Using the 
SAS statistical program (SAS Inc; Cary, NC), statistically significant differences among 
treatments or groups was determined employing a mixed model ANOVA. An a priori test 
of least significant differences (LSD) with a Tukey method of adjustment to control the 
experiment-wise error rate was used to determine significant differences between groups. 
Differences were considered significant at p≤0.05. In figures, different letters denote 
significance at p≤0.05.  
 
Table 1. List of real time primers used in ChIP 
Name  Sequence (5‘ → 3‘) 
-143/+6 Forward GGCGAACACATCTGCATTTA 
Reverse GTTGCTCAGGTGTTGCTTGA 
-177 / -69 Forward CTCCCCAACCTTTCCATCT 
Reverse CGTGATCACTGCCACCTCT 
-607 / – 478 Forward GCAGCTGACTGCCAGTTTGT 
Reverse CTTGGATCCACTGCAGAACC 
-1065 / -859 Forward TTTAAACACGACCTGGAGCAGAAAAA 
Reverse ATTTCCAAGAGCAGCATCATCAC 
-1436 / -1299 Forward ATGATCCTTTGGGTTGCACA 
Reverse GTTTTGTTTCCCCTGCTTGC 
-2187 / -2037 Forward AGGGGAAACTGTGAGCAAAC 
Reverse GAAGGCTGAAATGCTCTCCT 











The effects of CORT on covalent modifications of GH-associated histone H3 
were evaluated using ChIP. Using the same assay, CORT-regulated recruitment of 
transcription factors (GR, Pit-1, and Ets1) to their putative binding sites on the GH 
promoter was also assessed. To characterize the temporal and spatial modifications of 
histone H3 and recruitment of the above mentioned transcription factors, ChIP analysis 
was performed on e11 chicken primary pituitary cells treated with CORT for different 
time points (0 h, 1.5 h and 6 h). The time points reflect CORT induction of GH mRNA 
expression. As reported previously, in response to CORT, GH mRNA levels in cultured 
primary pituitary cells begin to increase around 1.5 h, and reach the maximum peak at 6 h 
(135). The shorter time point was included to allow detection of histone modifications 
that may be transient. The 0 h time point served as the control. About 2kb of the 5‘-
flanking region of the GH promoter was analyzed by ChIP. Six real time primer pairs 
were designed to screen a distance of 2kb upstream of the GH transcription start site, 




Figure 11. Schematic representation of the chicken GH gene promoter showing primer 
pairs used in quantitative real time PCR. Also indicated are the positions of the GCRR, 




Primers to glyceraldehyde 3- phosphate dehydrogenase (GAPDH) were used as a control 
for histone modifications. GAPDH also served as a negative control for transcription 
factor recruitment and binding. The real time primers were designed at approximately 
300-350bp intervals.  
 
CORT increases histone H3 acetylation at both proximal and distal Pit-1 sites and the 
TSS 
It is widely accepted that histone modifications influence chromatin remodelling 
and promoter activation. Histone H3 acetylation at lysine residues 9 or 14 (K9 or K14) by 
histone acetyltransferases (HATs) is often linked to transcriptional activation. We 
hypothesized that CORT increases GH mRNA levels by increasing transcriptional 
activity at the GH promoter through an increase in H3 acetylation. To explore this 
hypothesis, ChIP experiments were performed on e11 chicken primary pituitary cells 
cultured in the presence or absence of CORT for 0 h, 1.5 h, or 6 h, using antibody 
directed against H3-K9/14 acetylation. The results are summarized in Fig 12(a). Effect of 
CORT on H3 acetylation was compared to the basal (0 h time point) within a single 
region. We found that treatment with CORT (1nM) for 1.5 h significantly enriched 
histone H3 acetylation signal at the distal Pit-1 site (-607/-478), proximal Pit-1 site (-
177/-69), and the TSS (-143/+6) (n=6, p<0.05). There was no effect of CORT treatment 
on histone H3 acetylation in regions further upstream from the TSS, including the GCRR 




sites and the TSS returned to basal levels. Overall, 1.5 h CORT treatment increased 





Figure 12. Effects of CORT treatment (0 h, 1.5 h, and 6 h) on histone acetylation (a), tri-
methylation of lysine 4 (b), and tri-methylation of lysine 27 (c). For each, real time PCR 
results are presented as percent input. Values with different letters indicate a significant 
difference (a; n=6, b; n=3, c; n=3 independent experiments) (p<0.05). Real time PCR 




CORT-dependent increase in H3me3K4 and reduction in H3me3K27 
Next, we examined a second histone H3 modification associated with gene 
activation, tri-methylation of lysine 4 (H3me3K4; Fig 12b). ChIP assay was performed 
using antibodies specific for H3me3K4 (Fig 12b). We found significantly enhanced 
H3me3K4 at the proximal Pit-1 site and the TSS in response to 1.5 h CORT treatment 
(n=3, p<0.05). 1.5 h CORT treatment caused ~ 3- to 3.5- fold increase in H3me3K4 at 
both sites. H3me3K27 states were also examined (Fig 12c). H3me3K27 is generally 
associated with gene repression. 1.5 h CORT treatment resulted in reduced H3me3K27 at 
the proximal Pit-1 and TSS sites. The CORT-induced increase in H3me3K4 at the 
proximal Pit-1 and TSS sites was consistent with the CORT-induced decrease in 
H3me3K27 signals (n=3, p<0.05). No differences in H3me3K4 or H3me3K27 states 
were observed at any other sites.  
 
Recruitment of RNA Pol II 
 Next, we investigated if there was a correlation between recruitment of RNA 
polymerase II and gene activating histone H3 modifications. As shown in Fig 13, 1.5 h 
CORT treatment increased recruitment of RNA Pol II to the TSS (n=3, p<0.05). The 










Figure 13. RNA polymerase recruitment to the chicken GH promoter in response to 
CORT treatment for different time points (0 h, 1.5 h, and 6 h). For each, real time PCR 
results are presented as percent input. Values with different letters indicate a significant 
difference (n=3 independent experiments; p<0.05). Real time PCR products after 40 
cycles from one replicate were visualized in an agarose gel.  
 
CORT regulates GR, Ets1, and Pit-1 association with the GH promoter 
 Knowing that Pit-1 sites and the GCRR site with its GRE-half site and Ets1 site 
are important for GH gene expression, we tested whether GR, Ets1, and Pit1 are recruited 
to their respective binding sites in response to CORT. Results are summarized in Fig 14a. 
Under basal conditions, Pit-1 was associated with the distal Pit-1 site. In response to 1.5 h 
CORT treatment, we detected increased Pit-1 binding to the proximal Pit-1 site, and 
decreased Pit-1 binding to the distal Pit-1 site (n=5, p<0.05). Further, under basal 
conditions, Ets-1 and GR were associated with the GCRR of the GH gene, and 1.5 h 
CORT treatment increased GR recruitment to the GCRR (n=5, p<0.05). Interestingly, 1.5 
h CORT treatment also increased GR binding to the distal Pit-1 site (n=5, p<0.05). 
Surprisingly, 6 h CORT treatment resulted in dissociation of Ets1 from the GCRR site 









Figure 14. Recruitment of transcription factors to the chicken GH promoter in response to 
CORT treatment. (a) GR, Pit-1, and Ets1 (b) Real time PCR results using primers against 
nascent GH transcript (+456/+596) and GAPDH. ChIP on e11 chicken pituitary cells 
looking at recruitment of transcription factors in response to CORT treatment for 0 h, 1.5 
h, or 6 h. Real Time PCR results presented as percent input. Values with different letters 
indicate a significant difference (n=5 independent experiments; p<0.05). Real time PCR 




Primers to the 3‘ region of the nascent GH transcript (region +456/+573) and GAPDH 
promoter were used as negative controls (Fig 14b). None of the factors bound to either of 
these regions. Overall, these results indicate that CORT regulates Pit-1, Ets1 and GR 




The aim of this study was to determine if CORT-induced increase in GH 
transcription involves histone modifications and recruitment of specific transcription 
factors to the GH promoter. Previous work has shown indirect involvement of epigenetic 
modifications in somatotroph differentiation (1, 213). To the best of our knowledge, there 
have been no studies conducted investigating the epigenetic modifications with respect to 
glucocorticoid regulation of the GH gene in any species. Using ChIP on cultured 
embryonic chicken pituitary cells, we evaluated CORT-dependent histone modifications 
as well as transcription factor recruitment to the 5‘-flanking region of the GH gene. 
Importantly, we demonstrate for the first time changes that occur on the endogenous 
chicken GH gene in response to CORT. We believe that glucocorticoid- stimulated 
histone modifications together with recruitment of transcription factors and RNA Pol II 
are important events leading to GH mRNA expression.  
Histone modifications play an important role in regulating gene transcription 
(146, 149, 150, 216). Histone H3 tails undergo several different modifications, including 
acetylation, tri-methylation and phosphorylation, and the state of chromatin is controlled 




methylation are two well-established modifications associated with activation of gene 
transcription (217). Consistent with the idea that CORT increases GH gene transcription 
through histone modifications, our results show that CORT treatment indeed increases 
histone acetylation at the TSS and proximal Pit-1 site of the 5‘-flanking region of the GH 
gene. Like acetylation of histone H3, tri-methylation of H3 lysine 4 is also associated 
with actively transcribed genes (218-221), while tri-methylation of H3 lysine 27 marks 
gene silencing or a repressed state (222, 223). We demonstrate that CORT increases tri-
methylation of lysine 4 at the GH TSS. The pattern of lysine 27 tri-methylation was 
opposite to that of tri-methylation of lysine 4. The histone H3 trimethylation of lysine 4 
and acetylation results taken together support a role for these modifications in active 
transcription of GH gene in response to CORT treatment. The acetylation and tri-
methylation results correlate with the observed RNA Pol II recruitment, which further 
supports the idea that CORT enhances GH gene transcription through dynamic changes 
in chromatin structure through histone modifications.   
GR, Pit-1, and Ets1 are important transcription factors involved in GH gene 
expression, and each has putative binding sites in the 5‘-flanking region of the GH gene. 
Deletion of the GCRR or mutation of its Ets1 or GR-binding sites significantly attenuates 
CORT induction of GH promoter activity (141). Further, Ets1 and GR association with 
their putative binding sites within the GCRR have also been confirmed by EMSA, further 
supporting our ChIP results (141). Our overall results can be summarized into three states 






A) Basal : 
 
 











Figure 15. Proposed model for histone modifications and transcription factor recruitment 
to the 5‘-flanking region of the GH gene in response to CORT. (A) Basal: Chromatin is 
highly trimethylated on lysine 27 of H3, a marker for repressed or inactive state. The TSS 
is not accessible. GR is found in the cytoplasm. Pit-1 is bound to distal Pit-1 site, and 
Ets1 is associated with the GCRR. (B) 1.5 h CORT: GR translocates to the nucleus and 
binds to the GCRR. In addition, CORT increases Pit-1 recruitment to the proximal Pit-1 
site. CORT-induced histone acetylation and tri-methylation of lysine 4 opens up the 
chromatin. RNA Pol II is recruited to the TSS, and switches ‗ON‘ gene transcription. (C) 
6 h CORT: Ets1 dissociates from the GCRR. Transcription factors GR and Pit-1 also 
dissociate, as does RNA Pol II. Increased chromatin deacetylation along with increased 






Under basal conditions, Pit-1 is bound to the proximal and distal Pit-1 sites, but Pit-1 
alone may not be sufficient for GH expression. The TSS is likely inaccessible with 
histone H3 highly trimethylated at lysine 27. This keeps the chromatin in a closed 
inactive state. Ets1 is bound to the GCRR, and we hypothesize that Ets1 may have a role 
in maintaining a repressed state of GH gene transcription. The unliganded GR stays in the 
cytosol, although under basal conditions some GR is bound to the GCRR and the distal 
Pit-1 sites. Even though some studies have suggested that Pit-1 is predominantly found in 
the nucleus, the mechanism of CORT regulation of Pit-1 remains largely unknown. 
Nevertheless, we have shown here that some Pit-1 is bound to both distal and proximal 
Pit-1 sites in the GH promoter, even under basal conditions. In the presence of CORT, 
CORT binds to GR and activates it. Liganded GR translocates to the nucleus, and binds 
to the GCRR. Ets1 may be displaced, but our ChIP results suggest it is still bound to the 
GCRR region. There is a substantial increase in histone acetylation and histone tri-
methylation of lysine 4 at both the proximal Pit-1 and the TSS sites, and tri-methylation 
of lysine 27 decreases, conferring an open and more active chromatin state. There is 
concomitant increased Pit-1 binding to the proximal Pit-1 site consistent with the idea 
that Pit-1 is required for GH expression. Further, there is a correlated increase in RNA 
Pol II recruitment, again in accordance with the idea of increased transcription. GR 
recruitment to the distal Pit-1 site and Pit-1 recruitment to the proximal Pit-1 site raise 
several interesting propositions. The obvious question being: Is there an interaction 
between GR, Ets1, and Pit-1, and is this crosstalk important for GH gene regulation? This 




The mechanism by which CORT induces histone modifications near the TSS of 
GH gene remains to be answered. In e11 pituitary cells, treatment with histone 
deacetylase inhibitors HC toxin or TSA completely blocked CORT induction of GH 
mRNA, consistent with our results (142). It is important to note that in our studies 
acetylation of histone H3 was decresed at 6 h, which provides additional support for 
involvement of HDACs in the process. It is known from previous studies that GR 
interacts with histone modifiers (HATs and HDACs) and may indirectly regulate gene 
transcription in a tethered manner. The CREB binding protein (CBP) and p300 are 
important GR modulators and interacting partners with intrinsic HAT activity (108). The 
p300/CBP associated factor (P/CAF) is the other HAT that is known to interact with GR 
(224). Other than the HATs, GR-mediated activation of genes also involves coactivator-
associated arginine methyltransferase 1 (CARM1), a histone H3 methyltransferase (225-
227). In mice, the lysine demethylase LSD1 is suggested to interact with WD repeat 
domain 5 (WDR5) factor, a component of the myeloid/lymphoid or mixed-lineage 
leukemia (MLL1) coactivator complex in the GH promoter. The MLL1 coactivator 
complex consists of four elements: MLL1 (a histone methyltransferase), RbBP5 
(retinoblastoma binding protein 5), Ash2L (ash2 (absent, small, or homeotic)-like), and 
WDR5, and this complex catalyzes histone H3 methylation (1, 154, 174). Overall, GR-
mediated histone modifications have been demonstrated in other genes, and our findings 
indicate that similar GR-mediated factors may be involved in regulating the GH gene in 
chicken embryos. Further studies are required to characterize the detailed molecular 
mechanisms of these actions. Based on our results, GR is found bound to the GCRR and 




along with increased Pit-1 binding to the proximal Pit-1 site. From previous work 
reported by others about GR-interacting partners (224), we can speculate that GR may be 
recruited or bound to the GH promoter as part of a large complex consisting of factors 
with intrinsic HAT activity such as CBP/p300, etc. In response to CORT, a cascade of 
events is initiated, including additional recruitment of GR to the GCRR site and Pit-1 to 
the proximal Pit-1 site. This is followed by RNA Pol II recruitment and HAT- and 
histone methyltransferases-dependent histone H3 modifications that result in increased 
histone H3 acetylation and trimethylation. These events finally lead to the recruitment of 
basal transcriptional factors and GH gene transcription.   
This study is the first of its kind in characterizing histone modifications in 
association with transcription factor recruitment to the GH promoter. The direct 
interacting partners involved in CORT-mediated regulation of GH transcription are yet to 
be identified, but this study does provide the basis to investigate possible protein-protein 
interactions on the GH promoter. Protein-protein interactions not limited to GR, Pit-1, 
and Ets1 also need to be investigated. In summary, our results demonstrate CORT-
















Characterization of chicken Dexras1 and its potential involvement in 












Glucocorticoid (CORT) induction of growth hormone (GH) in the anterior 
pituitary of embryonic chickens requires ongoing protein synthesis. Microarray screening 
conducted on 14,053 unique chicken cDNAs identified Dexras1 as a novel candidate 
possibly involved in regulating GH expression in response to glucocorticoids. The aim of 
this project was to characterize chicken Dexras1 and its effects on CORT-mediated GH 
regulation. Dexras1 was only recently identified and is not well characterized in any 
species, and importantly Dexras1 has not been previously studied in the context of 
pituitary functions. We have confirmed expression of endogenous Dexras1 mRNA in 
both caudal and cephalic lobes of the chicken anterior pituitary, specifically within 
somatotroph and corticotroph pituitary cell-types. Further, CORT induction of Dexras1 
involves glucocorticoid receptor (GR) and requires both MEK1/2 and Ras cell signalling 
pathways. The effect of overexpression of Dexras1 on GH promoter activity as well as 
GH mRNA levels was examined. Dexras1 (1µg of vector) alone did not influence the 
activity of a 1727bp-GH reporter. In contrast, overexpression of Dexras1 (1µg of vector) 
significantly inhibited CORT-induced GH mRNA levels, while lower doses of Dexras1 
plasmid (10ng and 100ng) stimulated basal GH expression. This effect was specific to 
GH and did not include mRNA levels for other hormones or CORT-regulated genes. 
Downstream targets of Dexras1 in this GH effect are not clear. Knowing that ERK1/2 
signalling is required for CORT induction of GH, effects of Dexras1 expression on a 
well-established ERK1/2 effector, Elk-1 were investigated. Dexras1 overexpression did 
not affect phosphorylation of Elk-1 as examined in LMH (Leghorn male hepatoma) and 




somatotroph cells of the anterior pituitary in chickens that exhibits a potential role in 
regulating GH expression. The molecular mechanism of GH mRNA regulation by 
Dexras1 needs further investigation.  
Introduction 
Regulation of growth hormone (GH) expression by corticosterone (CORT) during 
development in embryonic chicken pituitary cells is an indirect effect requiring ongoing 
protein synthesis (135). The GH secreting somatotroph cells in the anterior pituitary 
appear around embryonic day (e) 12 in chickens (39), and somatotroph differentiation 
can be prematurely induced by CORT treatment (124). Ontogeny of GH-producing cells 
correlates with an increase in serum CORT levels in chickens, further supporting the 
importance of CORT in GH regulation (28, 228). In cultured embryonic chicken pituitary 
cells, GH mRNA levels are significantly increased within 6 h of CORT treatment (135). 
In a microarray study conducted to identify possible genes mediating the effects of 
CORT on GH expression, Dexras1 was selected as a potential candidate (176). Dexras1 
was selected, because it is directly regulated by CORT and because Dexras1 mRNA 
levels were significantly enhanced within 6 h of CORT treatment. In addition, the 
ontogeny of Dexras1 correlates with that of GH and CORT in developing chicken 
embryos (140, 175, 176). Furthermore, CORT induction of GH mRNA expression was 
completely blocked in the presence of manumycin, a ras inhibitor, suggesting that ras 
signalling or a ras-like factor is required for CORT induction of GH expression (135). 
The requirement for a ras-like factor made Dexras1 an even more interesting candidate to 




Dexras1 is a guanine triphosphate (GTP)-binding protein first identified in AtT-20 
corticotroph cells as a CORT-inducible gene (177). Subsequently, Dexras1 has been 
identified in several other species, including humans (180, 229), rodents (181, 230), and 
chickens (175, 176). The mechanism of CORT induction of Dexras1 and the downstream 
signalling targets of Dexras1 are largely unknown. The regulation of Dexras1 by CORT 
appears to be at the gene transcription level and occurs in a dose-dependent manner 
(177). Although a glucocorticoid response element (GRE) has been identified in the 3‘-
flanking region of the human Dexras1 gene (229), sequence analysis of 5‘- and 3‘- 
flanking regions of chicken Dexras1 did not reveal a conserved GRE (176). Dexras1 
belongs to the family of activators of G protein signalling (AGS) and is structurally 
similar to that of other ras proteins, except that it contains an extended carboxyl terminus 
(177, 180, 195, 197). The role of Dexras1 appears to be very complicated, and it has been 
shown to exhibit different ligand-dependent and ligand-independent (or basal) signalling 
(86, 188, 190, 192, 198, 200). Dexras1 has been proposed to act as a guanine exchange 
factor (GEF) and promote ligand-independent activation of the Gβγ signalling effector 
and extracellular signal-regulated kinases 1/2 (ERK1/2), while at the same time 
suppressing the receptor-dependent activation of the same signalling pathway.  
 Some reports suggest a role of Dexras1 in pituitary hormone secretion (195).  In 
pituitary corticotrophs, the negative feedback regulation of ACTH secretion by CORT 
may involve Dexras1. Further, a constitutively active form of Dexras1 in AtT-20 cells 
suppressed cAMP-stimulated secretion of transiently overexpressed GH (195). Chicken 
Dexras1 is highly similar to known species like human, mouse, and rat. It contains all 




terminal CAAX domain. Dexras1 mRNA in juvenile chickens was only found in the 
pituitary (176).  
The aim of this work was to identify potential roles of Dexras1 in regulating 
chicken GH expression. In addition, we examined whether Dexras1 may play a role in 
regulating expression of other pituitary hormones. We confirmed expression of Dexras1 
in chicken pituitary cells. Glucocorticoid regulation of Dexras1 mRNA expression was 
also addressed. We tested the involvement of some of the known cell signalling pathways 
in glucocorticoid regulation of Dexras1 expression, and defined the role of GR and 
mineralocorticoid receptor (MR) in this process. Dexras1, like other ras proteins, has 
been shown to undergo post-translational modifications such as prenylation. Prenylation 
in ras proteins results in the translocation of the ras protein factor to the plasma 
membrane (182). Although, functioning of Dexras1 does not necessarily always depend 
on its translocation to the plasma membrane in all systems, we tested whether CORT 
treatment results in Dexras1 translocation or causes a change in its cellular localization. 
Our study provides evidence for Dexras1 mRNA expression in chicken pituitary cell 
types, an understanding of the processes that regulate Dexras1, and identifies a novel 
potential role for Dexras1 in regulating GH expression.  
 
Materials and Methods 
Chicken pituitary dissection and dispersion 
All chicken embryo protocols were approved by the Institutional Animal Case 




60% humidified, 37 C incubator. The first day of incubation was defined as embryonic 
day (e) 0. Pituitaries were collected from e11, e17 or e18 (depending on the experiment) 
embryos. An e11 chicken pituitary yields approximately 300,000 cells, while an e17-e18 
pituitary yields about 850,000 cells. Anterior pituitary tissues were trypsin digested to 
obtain a single cell suspension as previously described (39). Cells were counted using the 
trypan blue exclusion method, and the viability rate was above 95% in all experiments. 
To define Dexras1 expression within the anterior pituitary cells, caudal and cephalic 
pituitary lobes from e18 chicken embryos were dissected under light microscopy. The 
lobes were snap frozen with liquid nitrogen and stored at -80 C for total RNA extraction.   
Cell culture 
Primary chicken pituitary cells (e11, e17, or e18) after trypsin digestion were 
plated on poly-L-lysine coated 12-well or 24-well plates (Corning Life Sciences, Lowell, 
MA). In the case of experiments that did not involve transfection, dispersed pituitary cells 
were plated and allowed to attach for 1 h in a 37 C incubator in serum-free Dulbecco‘s 
modified Eagle‘s medium/Ham‘s nutrient mixture F12 (DMEM/F12) supplemented with 
0.1% bovine serum albumen (BSA), 5μg/ml human insulin, 100 U/ml penicillin G, and 
100μg/ml streptomycin sulfate, before treatment with any hormones, inhibitors or 
activators. GH4C1 cells, a rat pituitary cell line, were maintained in DMEM/F12 medium 
supplemented with 12.5% horse serum and 2.5% fetal bovine serum in 75-cm
2
 flasks. 
LMH cells, a chicken hepatocellular carcinoma epithelial cell line, were maintained in 







For GR and MR studies, intracellular GR and MR signalling were inhibited using 
antagonists, ZK98299 (kindly supplied by Schering AG, Berlin, Germany) and 
spironolactone (Sigma), respectively. Both inhibitors were used at 100nM. Cells were 
pretreated with antogonists for 1 h followed by CORT (1nM) treatment, as indicated.  
For intracellular signalling pathway studies, the following inhibitors and 
activators were used: LY294002 (PI3-K inhibitor, 50μM), U0126 (ERK1/2 inhibitor; 
10μM), manumycin A (ras inhibitor; 1μM), anisomycin (p38/JNK MAPK activator; 
10µM), EGF (receptor tyrosine kinase activator; 100ng/ml), forskolin-IBMX (PKA 
activator; 1µM), and phorbol-12-myristate-13-acetate (PMA; PKC activator; 1µM). Cells 
(1x10
6
/well in a 24-well plate) were pretreated with vehicle (DMSO) or inhibitors for 1h 
before addition of CORT (1nM) for 3 h. In the case of activators, no pretreatment was 
performed. CORT and activators were added together for 3 h. In experiments evaluating 
levels of phosphorylated Elk-1, 24 h after transfection, LMH or GH4C1 cells (5x10
6
/well 
in a 12-well plate) were left untreated (basal) or treated with CORT (1nM) or EGF 
(100ng/ml) for 3 h.  
 
Plasmids and transfection  
The reporter construct used to analyse GH promoter activity was kindly provided 
by Dr. F. Leung (University of Hong Kong). The -1727 to +48 bp sequence of the 
chicken GH gene driving firefly luciferase (pGL3-1727) has previously been 
demonstrated to be responsive to dexamethasone in GH4C1 cells (137) and to CORT in 




the normalization plasmid constitutively expressing renilla luciferase (pRL-SV40) used 
in promoter analysis studies were purchased from Promega (Madison, WI). 
 Dexras1 cDNA was non-directionally subcloned into the CMV promoter driven 
pCMV-Sport6.1 expression vector (Sport6.1; Invitrogen) or into pEYFP-C1 expression 
vector (for N-terminal YFP tagging, kindly provided by Dr. Iqbal Hamza, University of 
Maryland). Primers (Sigma Aldrich) used for PCR amplification of the coding region are 
given in Table 2. PCR amplification to generate insert was conducted using AccuPrime 
Pfx SuperMix (Invitrogen) according to the manufacturer‘s protocol. PCR cycling 
parameters were as follows: 95 C for 5 min; 35 cycles of 95 C for 15 s, 58 C for 45 s, and 
68 C for 2 min; and a final extension at 68 C for 5 min. Products were digested using 
EcoRI restriction enzyme. Clones were screened using PCR for directionality of the 
insert using vector specific and insert specific cloning primers. A clone with the 
appropriate insert in the correct orientation was purified using the NucleoBond PC 500 
plasmid purification kit (Macherey-Nagel, Inc., Bethlehem, PA). All clones were 
sequenced in their entirety by the sequencing center at the University of Maryland‘s 
Center for Biosystems Research.  
 All transfections were performed in supplement-free optimized modified Eagle‘s 
minimal essential medium (OptiMEM I) using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer‘s protocol. For studies investigating the effect of Dexras1 
overexpression on GH promoter activity, 5x10
5
 e11 pituitary cells per well in a 12-well 
plate were allowed to attach for 1h in supplement-free OptiMEM I medium, followed by 
transient transfection with Lipofectamine 2000. The transfection medium was formulated 




reporter plasmid (pGL3-1727 or pGL3-Basic), 20ng pRL-SV40 and 4μl Lipofectamine. 
Cells were transfected for 6 h, and after 6 h, the medium was replaced with DMEM/F12 
cell culture medium. Cells were allowed to recover for at least 16 h, followed by CORT 
(100nM) treatment for 20 h.  
 For experiments investigating effects of Dexras1 on GH mRNA expression, e11 
pituitary cells (3 x 10
6
 cells in a 12-well plate) were co-transfected with 1μg of golgi-
targeted green-fluorescent protein (GFP) expression vector and 1μg  Sport6.1 or Dexras1 
expression plasmid in transfection medium as before (OptiMEM I with 4μl 
Lipofectamine). Cells were transfected in suspension for 2 h, followed by 4 h of 
transfection in the plate (total 6 h of transfection). At the end of 6 h of transfection, 
medium was removed and replaced with DMEM/F12 cell culture medium. After 16 h of 
recovery, cells were treated with CORT (1nM) for 20 h. GFP was used as a marker to 
collect positively transfected cells by fluorescence activated cell sorting (FACS). After 20 
h of CORT treatment, cells were retrypsinised and washed once with ice-cold phosphate-
buffered saline (PBS). Cells were resuspended in 0.25ml of ice-cold PBS until FACS 
sorting.  
 Transfection of LMH and GH4C1 cells were similarly conducted using 
Lipofectime2000 in plates. For confocal microscopy, LMH or GH4C1 cells were plated 
on coverslips placed on the bottom of a 6-well plate, and transfected with 2μg of EYFP-
Dexras1 expression plasmid for 6 h in OptiMEM-I with 8μl of Lipofectamine. After 6 h 
of transfection, medium was replaced with cell culture medium, and cells were allowed to 




To investigate the effects of Dexras1 on phosphorylation of p-Elk-1, LMH and 
GH4C1 cells were plated (12-well plate) overnight, and transfected when 90% confluent 
with 1μg of pSport6.1 or Dexras1 expression plasmid for 6 h in OptiMEM I with 4ul of 
Lipofectamine. After 6 h of transfection, medium was replaced with appropriate cell 
culture medium (Waymouth for LMH or DMEM/F12 for GH4C1 with supplements). 
Cells were allowed to recover for at least 16 h. Cells were then left untreated (basal) or 
treated with EGF (100 ng/ml) or CORT (1nM) for 3 h followed by cell lysis for protein 
analysis.   
Intracellular staining of hormone cell types  
Following dispersion, e17 pituitary cells (5x10
6
 cells per treatment) were 
subjected to intracellular staining using the BD Cytofix/Cytoperm™ Kit (#554714) with 
the following modifications. After dispersion, cells were resuspended in 250µl of 
cytofix/cytoperm buffer (3.7% formaldehyde), and incubated for 20 min at 4 C. Cells 
were washed twice in 250µl of Perm/Wash buffer, using centrifugation at 1000xg for 
5min for each wash. Primary unconjugated antibodies were diluted in the perm/wash 
buffer, and cells were resuspended in the primary antibody containing perm/wash buffer 
and incubated for 1 h at 4 C. All the hormone-specific primary antibodies have been 
previously characterized. Dilution of different antibodies used were as follows: rabbit 
anti-chicken GH (1:2000), rabbit anti-chicken
 





anti-chicken ACTH (1:1000), and mouse monoclonal
 
anti-
chicken  LHβ (1:1000). Cells were washed thrice (each time with 500µl of buffer) with 




anti-rabbit (1:100) or anti-mouse IgG (1:400) diluted in perm/wash buffer. Negative 
control samples were treated exactly the same, except they received only secondary 
antibody and no primary antibody. Samples were maintained in the dark from this point 
onwards. Finally, cells were washed thrice with perm/wash buffer, with 5 min 
centrifugation at 1000xg. Cells were resuspended in 200µl of perm/wash buffer and 
stored on ice until flow cytometric analysis.  
Confocal microscopy 
After transfection and recovery, LMH or GH4C1 cells were allowed to express 
protein for 48 h. Cells were kept in the dark. Cells were washed once with 1ml PBS at 
room temperature. Cells were labeled with 5µg/ml WGA conjugate Alexa Fluor 633 
(Molecular probes, #W21404 plasma membrane staining) for 10 min at 37 C, followed 
by two washes with 1 ml room temperature PBS. Cells were fixed with 3.7% 
formaldehyde in PBS for 15 min at room temperature, followed by three washes of 5 min 
(3x5 min) each with PBS. Next, cells were permeabilized with 0.1% Triton-X-100/0.1% 
Tween-20 in PBS for 8 min, and again washed 3x5 min. Nuclei staining was achieved 
with DAPI (300nM), staining for 5 min at room temperature followed by 3x5 min 
washing with PBS. After the final wash, coverslips were mounted on clean microscope 
slides using VectaShield Mounting Medium, and preparations were visualized using a 
Leica SP5 X Confocal Microscope in the Imaging Core facility on the University of 





Luciferase assay to measure promoter activity 
Cell culture medium was removed, and cells were washed once with PBS 
followed by cell lysis with 100µl of passive lysis buffer (Promega). Lysates were stored 
at -20 C until luciferase reporter activity was measured. Cell lysates (20μl) were analyzed 
for firefly (reporter gene) and renilla (normalization gene) enzyme activities using the 
Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer‘s 
instructions. Firefly luciferase activity was normalized to renilla luciferase activity, and 
promoter activity is represented as fold change over basal (pGL3-Basic, untreated).  
Flow cytometry 
 All flow cytometric analysis and sorting were conducted at the University of 
Maryland, Department of Veterinary Medicine‘s Flow Cytometry Core Facility. For 
Dexras1 overexpression studies, positively transfected cells were sorted based on GFP. 
For the hormone-based intracellular staining, cells were sorted based on FITC staining. 
Before sorting, cells were filtered through a 35µM nylon mesh to remove clumps. Cells 
were analyzed using a high-speed benchtop flow cytometer and cell sorter (FACSAria II; 
BD Biosciences). Data acquisition and analysis were performed with FACSDiva 
software. For Dexras1 overexpression experiments, approximately 50,000 GFP-positive 
cells per group were collected into 0.5ml of RLT buffer (RNeasy Mini Kit, Qiagen). 
Collected samples were maintained at room temperature until RNA extraction. 1μl of β-
mercaptoethanol per 100μl of RLT buffer was added to each sample immediately before 
RNA extraction using RNeasy Mini Kit as per the manufacturer‘s protocol. In the case of 




into 0.5ml of buffer PKD from the RNeasy-FFPE-kit (Qiagen) and maintained at room 
temperature until RNA extraction. 
 
Total RNA extraction, quantification and reverse transcription 
Total RNA was extracted from tissues stored at -80 C or immediately extracted 
following sorting. Extracted RNA was stored at -80 C. Total RNA extraction was 
conducted based on the manufacturer‘s protocol and included on-column DNase 
digestion. RNA yields for all the experiments were quantified using the Quant-iT 
Ribogreen RNA Reagent and Kit. Reverse Transcription reactions using total RNA were 
performed with SuperScript III (Invitrogen) and anchored-dT-one-V primer (Table 3.1). 
No reverse transcription (RT) controls were included that contained everything except the 
reverse transcriptase enzyme.  
Quantitative Real Time PCR (qRT-PCR) 
 Real Time PCR reactions were conducted using the MyiQ Single-Color Real 
Time PCR Detection System (Bio-Rad, Hercules, CA). Most of the real time PCR 
reactions were performed in either 15µl or 30µl volume. 1μl of complementary 
deoxyribonucleic acid (cDNA) was added to the PCR mix (400nM of each primer, PCR 
buffer: 50 mM KCl, 10 mM Tris-HCl, 0.1% Triton-X-100), 0.12 U/μl Taq Polymerase, 
200nM dNTPs, 40nM fluorescein (Invitrogen), and SYBR Green I Nucleic Acid Gel 
Stain (Invitrogen) diluted 1:10,000), and reactions were performed using the following 
conditions: denaturation at 95 C for 3 min, 40 cycles of 95 C for 15 s, 60 C for 30 s, and 




confirmed single PCR products for all reactions. The negative control (No RT) reactions 
did not contain any amplified products. The different primers used for the real time PCR 
reactions are listed in Table 2 given below:  
 
 
Table 2. List of primers used for cloning, sequencing, reverse transcription, and 










Beta-actin was used as a housekeeping gene for normalization of qRT-PCR results. The 
following equation was used for transformation and normalization of each target gene: 




)beta-actin, where ΔCt = CtnoRT – Ctsample. For overexpression 
studies, mRNA levels were normalized to beta-actin mRNA levels, and data are 
presented as mRNA fold change over basal. Values are presented as means+SEM. For 
detection of Dexras1 expression in different hormone cell types, mRNA levels were 
transformed and normalized to beta-actin mRNA levels as described above. Means of the 
transformed values for each gene from three independent replicates are presented relative 
to the mRNA level of beta-actin x 1000.   
 
Protein extraction and quantification  
 For phosphorylation of Elk-1 studies, total protein was extracted from LMH or 
GH4C1 cells transfected as described above using 500µl of 1X cell lysis buffer. Cell lysis 
buffer consisted of 20mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM Na2EDTA, 1mM 
EGTA, 1% Triton-X-100, 2.5mM sodium pyrophosphate, 1mM β-glycerophosphate, 
1mM Na3VO4, 1µg/ml leupeptin, and 1mM PMSF added just prior to use. Cells were 
rinsed one time with ice-cold PBS. Total protein was extracted in 250µl of ice-cold cell 
lysis buffer with agitation, followed by sonication (3x10 s with 30 s rest at output= 4 
continuous). Samples were centrifuged for 10 min at 14,000xg at 4 C, and supernatants 
were transferred into new tubes. Protein extracted was quantified using Pierce MicroBCA 






Protein samples were thawed on ice. 30μg of total cellular protein were boiled in 
Bio-Rad Laemmli sample buffer and loaded onto a 12% SDS-polyacrylamide gel. 
Proteins were resolved and transferred to a PVDF membrane (Immobilon-P; Millipore, 
Billerica, MA) using a Trans-Blot SD Semi-Dry Electrophoretic Transfer. Following 
transfer, membranes were washed for 15 min with Tris-buffered saline containing 
Tween-20 (TBS/T; 20mM Tris-HCl, 136mM NaCl, 0.1% Tween-20, pH 7.6), and 
blocked for 2 h at room temperature in TBS/T containing 5% nonfat dry milk. 
Membranes were washed 3 x 5 min in 1% nonfat dry milk in TBS/T and incubated over 
night at 4 C with primary phospho-Elk-1 (Ser383) antibody (1:1000, cell signalling 
#9181) or a mouse monoclonal antibody (1:500; Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA) against α-tubulin. Membranes were washed and incubated with horseradish 
peroxidase-conjugated anti-rabbit IgG (1:2000; Cell Signalling Technologies) or anti-
mouse IgG (1:5000; Amersham Biosciences; Piscataway, NJ) diluted in TBS/T 
containing 5% nonfat milk. Membranes were developed using enhanced 
chemiluminescent detection reagents (LumiGLO; Cell Signalling Technologies, Inc.) and 
the ChemiDoc XRS system.  
 
Statistics and data analysis 
For promoter activity and qRT-PCR data for mRNA expression studies, data are 
presented as fold change over basal, where basal refers to cells either at the 0-time point, 




activity was normalized to renilla luciferase activity. For expression studies, the Ct values 
were log-2 transformed (2
Ct
) and analyzed as indicated for the different studies. All data 
were analyzed using SAS software (SAS Institute) by analysis of variance using the 
MIXED models procedure, with differences between groups determined by the test of 
least significant differences (PDIFF). Differences are considered significant at P<0.05. 
 
Results 
Dexras1 is directly regulated by CORT in chicken embryonic pituitary cells 
 We have previously reported that Dexras1 has a similar developmental profile as 
that of GH in the chicken pituitary cells (175). A microarray study conducted to identify 
unknown factors involved in CORT regulation of GH, recognized Dexras1 as a potential 
CORT-induced factor (176). To confirm that Dexras1 is directly regulated by CORT, e11 
chicken primary pituitary cells were cultured in the presence or absence of 
cycloheximide, a protein synthesis inhibitor, and treated with CORT (1nM) for different 
time points (0 h, 1.5 h, 3 h, and 6 h). The 0 h time point was used as the basal control. 
Following treatment, total RNA was extracted, and Dexras1 mRNA levels were 
measured by qRT-PCR. Dexras1 mRNA levels were normalized to both basal and beta-
actin. As seen in the Fig 16, CORT treatment significantly increased Dexras1 mRNA 
levels by 1.5 h, and levels remained increased through 6 h (n=3; p<0.05). Dexras1 
induction by CORT was not affected by the presence of CHX, at least at 1.5 h and 3 h, 
indicating that Dexras1 mRNA induction by CORT does not require the synthesis of an 








Figure 16. Quantitative real time PCR results confirm CORT induction of Dexras1 
mRNA in cultured e11 chicken pituitary cells (n=3). E11 chicken pituitary cells were 
cultured in the presence or absence of CHX and treated with or without CORT (1nM) for 
0, 1.5 h, 3 h or 6 h. Dexras1 mRNA levels were measured and normalized to beta-actin 






CORT induction of Dexras1 mRNA involves GR  
Knowing that chicken Dexras1 is regulated by CORT, we next investigated the 
involvement of GR or MR in this process. CORT induction of target genes 
conventionally occurs through binding of CORT to GR or MR, and activated ligand-




We tested the requirement for GR and MR in CORT induction of Dexras1 expression 
using pharmacological inhibitors, spironolactone (MR inhibitor; 100nM) and ZK98299 
(GR inhibitor; 100nM). These doses of the inhibitors have been previously used in our 
system (98). E11 chicken pituitary cells were pretreated for 3 h with each inhibitor alone 
or in combination. Following pretreatment, cells were treated with CORT (1nM) for 1.5 h 
or 3 h. Substantial increases in Dexras1 mRNA were only observed with 3 h of CORT 
treatment, although there was a 2-fold increase in Dexras1 mRNA levels in response to 
1.5 h CORT (n=3, p<0.05). Addition of spironolactone significantly increased Dexras1 
mRNA levels even under basal conditions, and this was further augmented by the 
addition of CORT for 3 h (Fig 17). The CORT-induced increase in Dexras1 mRNA 
levels was significantly reduced by the presence of ZK98299, indicating the involvement 
of GR (n=3, p<0.05). These results indicate that Dexras1 induction of CORT involves 
GR. The effects of spironolactone on Dexras1 mRNA induction are not clear but likely 
involve agonistic effects of this compound (98). 
CORT-induced increases in Dexras1 mRNA are attenuated by inhibitors of Ras 
signalling and the MEK1/2 pathway 
To define the molecular mechanism of CORT induction of Dexras1 mRNA 
expression, involvement of different cell signalling pathways in this process was 
investigated. The MAPK/ERK, PKA, PKC, ras, PI-3 kinase, and protein tyrosine kinase 
pathways were manipulated using the following activators or inhibitors: LY294002 (PI-3 











Figure 17. CORT-induced increase in Dexras1 mRNA levels involves GR in e11 chicken 
pituitary cells. E11 chicken pituitary cells were pretreated for 3 h with 100nM GR or MR 
inhibitors (ZK98299 and Spironolactone, respectively) as indicated, followed by 
treatment with or without CORT (1nM) for 0 h, 1.5 h or 3 h. Dexras1 mRNA levels were 
measured and normalized to beta-actin mRNA levels as well as the basal untreated 
samples. Values with different letters indicate significant difference from one another 




1µM), anisomycin (p38/JNK MAPK activator; 10µM), EGF (receptor tyrosine kinase 
activator; 100ng/ml), forskolin-IBMX (PKA activator; 1mM), and phorbol-12-myristate- 
13-acetate (PMA, PKC activator; 1µM). E11 chicken pituitary cells were pretreated with 




was no pretreatment. Cells received activators and CORT (1nM) and were treated in 
combination for a total of 3 h. Data represent mRNA levels normalized to beta-actin and 
DMSO-treated control samples (Fig 18). None of the pathway activators had any effect 
on CORT-induced Dexras1 mRNA levels (n=3). Inhibition of PI3-K did not change the 
CORT-induced increase in Dexras1 mRNA levels (p>0.05). Ras pathway inhibition by 
manumycin or MEK1/2 inhibition by U0126 significantly reduced the CORT-dependent 
increase in Dexras1 mRNA levels (n=4, p<0.05). These results indicate that CORT 
induction of Dexras1 mRNA in embryonic chicken pituitary cells does not require the 
PKA, PKC or PI3-K signalling cascades, but may involve ras or a ras-like compound and 
MEK1/2 signalling. 
Cellular distribution of Dexras1 mRNA expression in embryonic chicken pituitary cells 
 Pituitary Dexras1 mRNA levels increase concomitantly with expression of GH 
during chicken embryonic development (175), and CORT indirectly induces GH mRNA 
(135), while its effects on Dexras1 expression do not require ongoing protein synthesis. If 
Dexras1 is to play a functional role in regulating expression of hormone genes during cell 
type differentiation in the pituitary, then expression of Dexras1 in the particular cell type 
may be considered as a prerequisite. Since chicken Dexras1-specific antibody was 
unavailable, two indirect methods were employed to examine the cellular distribution of 
Dexras1. For the following experiments, Dexras1 mRNA expression was tested in e17 or 
e18 chicken embryos, when expression levels are greatest and all pituitary cell types have 
differentiated (27, 175, 228). The anterior pituitary in birds has two distinct lobes – 
caudal and cephalic. Somatotrophs are present in the caudal lobe, while corticotrophs, 









Figure 18. Involvement of endogenous cell signalling pathways in CORT induction of 
Dexras1 mRNA in cultured chicken e11 pituitary cells. E11 chicken pituitary cells were 
cultured in the presence or absence of the different activators (anisomycin, EGF, 
forskolin and PMA; n=3) and inhibitors (LY294002, U0126 and manumycin; n=4) as 
indicated, followed by CORT treatment for 3 h. Dexras1 mRNA levels were normalized 
to beta-actin mRNA levels. Data values (Means + SEM) with different letters are 
significantly different (P<0.05). 
 
 
To assess whether GH-producing somatotroph cells express Dexras1, caudal and cephalic 
lobes from e18 chickens were isolated and analyzed separately (n=3). As expected, GH 
mRNA levels were highly enhanced in the caudal lobe, and POMC, PRL and TSHβ 
mRNA levels were enriched in the cephalic lobe (Fig 19). Dexras1 mRNA was detected 




expressed in more than one cell type in e18 chickens, suggesting it may play a role in 
regulating multiple cell types. 
In a second approach investigating the cell type distribution of Dexras1 mRNA, 








Figure 19. Dexras1 mRNA is expressed in both caudal and cephalic lobes of e18 chicks 
(n=3). Levels of GH, POMC, PRL, TSHβ, and Dexras1 mRNA were quantified by 
quantitative real time PCR for both lobes. Data are presented as a percentage of the lobe 
with highest expression of that gene. Within each gene, the mRNA level in the lobe with 
highest expression is fixed at 100%. Asterisk (*) represents higher expression levels of 







produced by each cell type. E17 chicken pituitaries were dispersed, washed, and stained 
for a particular hormone (GH, POMC, TSH, LH, and PRL). There were five experimental 
 groups (~10
7
 million cells per group), and each group was stained with a primary 
antibody against a particular hormone followed by FITC-conjugated secondary antibody. 
The control groups used for background detection received only the secondary FITC-
antibody. Each group was sorted separately, and negative and positive cells from each 
group were collected into tubes for RNA extraction. Within each group, the positive cells 
represent cells that were positively stained for a particular hormone. For example, 
positive cells collected from the group stained with POMC represent the corticotrophs. 
The negative cells collected from the same group will therefore contain all the other cell 
types. A representative result from FACS sorting is shown in Fig 20. The whole 
experiment was repeated three times. Dexras1 mRNA level was measured in each 
collected population. GH, POMC, TSHβ, LHβ, and PRL mRNA were also measured for 
each to confirm the purity of the collected sample. The positive cells were all enriched for 
the respective hormone for which they were sorted. Cross-contamination between 
different cell types in the collected samples was very low. Dexras1 mRNA was detected 
in both somatotroph and corticotroph cells as shown in Fig 21 (n=3, P<0.05). 
 
Subcellular localization of YFP-tagged Dexras1 in response to CORT treatment in LMH 
and GH4C1 cells 
 To test whether CORT has an effect on the subcellular localization of Dexras1, 





   




Figure 20. Representative FACS sorting analysis using GH primary antibody in e17 
chicken pituitary cells. (A) Control cells with no treatment. (B) Cells with only secondary 
antibody (C) Cells treated with both primary and secondary antibody. Top panels: shows 
all the events for samples A, B, and C. Bottom panels: (A) No FITC signal for sample A. 
(B) No FITC signal for cells receiving only secondary antibody (background). (C) Cells 
stained with both primary and secondary antibody shows clear FITC signal. For each 
hormone, the positive cells (within the FITC box) and the negative cells (Neg box) were 


























Figure 21. Expression of POMC, GH, PRL, LHβ, TSHβ, and Dexras1 mRNA in FACS 
sorted e17 chicken pituitary cells. E17 chicken pituitary cells were subjected to 
intracellular staining using antibodies specific for POMC, GH, PRL, LHβ, and TSHβ 
followed by FITC-based FACS sorting. Positive and negative cells from each group were 
collected. For each group, mRNA levels for POMC, GH, PRL, LHβ, TSHβ, and Dexras1 
were measured and normalized to beta-actin mRNA levels. Values (Means+SEM) with 
different letters denote significant difference in Dexras1 mRNA levels. Asterisks (*) 
denote a significant difference in hormone mRNA levels for positive and negative cells 

















domain was undisturbed. N-terminal YFP-tagged Dexras1 was transfected into LMH and 
GH4C1 cells, which were then treated with CORT for 3 h. WGA-Alexa-633 flurophore 
was used to stain the plasma membrane, and DAPI was used to mark the nucleus. Cells 
were visualized using a Leica SP5X confocal microscope. Fig 22(A) shows YFP-tagged 
Dexras1 in GH4C1 cells. Under basal conditions, Dexras1 was found mostly in the 
cytoplasm close to the plasma membrane. Upon CORT addition, the YFP-Dexras1 signal 
was still seen bordering the plasma membrane. An apparent change in Dexras1 
localization was not detected in response to CORT. In the case of LMH cells (Fig 22 
(B)), YFP-tagged Dexras1 gave a more diffuse signal. It was distributed throughout the 
cell with a few concentrated spots within the nucleus. Upon CORT addition, there was a 
marked increase in YFP signal in the nucleus, although YFP signal was still found 
throughout the cell. Overall, in GH4C1 cells, CORT did not have a significant influence 
on the subcellular distribution of Dexras1, whereas in LMH cells, CORT treatment 
resulted in an increased nuclear localization of Dexras1.   
 
Effect of overexpression of Dexras1 on growth hormone reporter activity 
 To test whether Dexras1 is involved in regulating the GH promoter activity, a 
reporter construct (pGL3-1727) containing the CORT-responsive -1727 to +48 sequence 
of the chicken GH gene driving firefly luciferase was co-transfected into e11 chicken 
pituitary cells along with 1µg of Dexras1 expression plasmid. The cells were then treated 
with or without CORT (1nM) for 12 h, and firefly luciferase activity was measured. 
Results shown in the Fig 23(A) represent means from three independent experiments 















Figure 22. Subcellular distribution of YFP-tagged Dexras1 in GH4C1 (A) and LMH (B) 
cells. In both A and B, top panels are images of cells under basal conditions, and the 































Figure 23. Effect of overexpression of Dexras1 on GH reporter activity. (A) E11 chicken 
pituitary cells were transfected with pGL3-Basic or -1727bp reporter plasmid with or 
without 1µg of Dexras1 expression plasmid, followed by treatment with or without 
CORT(1nM). Values (Means+SEM) with different letters denote significant differences 
(n=3, p<0.05). (B) Effect of different doses of Dexras1 expression plasmid on reporter 
activity in GH4C1 cells (n=1).   




in promoter activity. Overexpression with 1µg of Dexras1 expression plasmid did not 
introduce a significant change in the reporter activity (P>0.05). It neither enhanced nor 
attenuated the CORT effect, suggesting that Dexras1 may not be altering the activity of 
the -1727 to +48bp region of the GH promoter. Since Dexras1 is a ras protein and its 
activity may depend on the availability of GTP in the cell, effects of different doses of 
Dexras1 expression plasmid (1ng, 10ng, 100ng and 1µg) were also tested in a similar 
reporter assay in GH4C1 cells (Fig 23B). Preliminary results (n=1) show that lower doses 
(1ng and 10ng) of Dexras1 expression plasmid induced luciferase activity (~2- and 3-fold 
respectively) under basal (in the absence of CORT) conditions, whereas 10ng and 100ng 
of Dexras1 plasmid decreased reporter activity under CORT- treated conditions. 
 
Overexpression of Dexras1 affects GH mRNA levels 
 To investigate the role of Dexras1 in regulating GH gene expression, the effect of 
overexpression of Dexras1 on GH mRNA levels in transfected e11 chicken pituitary cells 
was determined. In intial experiments, e11 chicken pituitary cells were co-transfected 
with 1µg of pSports6.1 empty vector or 1µg of Dexras1 expression plasmid along with 
1µg golgi-targeted GFP-expression plasmid. Cells were treated with or without CORT 
for 20 h post-transfection. Positively transfected cells were collected based on GFP using 
FACS. Total RNA was extracted from the sorted and collected cells, and levels of mRNA 
for GH, PRL, POMC, GILZ, FKBP51, and RasDVA were measured by qRT-PCR. As 
shown in the Fig 24, CORT treatment (1nM) alone increased GH mRNA levels by ~ 40 
fold. Dexras1 overexpression significantly decreased the CORT-induced increase in GH 








Figure 24. Effect of overexpression of Dexras1 expression plasmid on mRNA levels. E11 
chicken pituitary cells were co-transfected with Dexras1 expression plasmid (1µg) or 
empty vector (pSport) and GFP-plasmid, and treated with or without CORT (1nM). 
Positively transfected cells were FACS sorted, and RNA was extracted from collected 
cells. Values (Means+SEM) are represented normalized to beta-actin. Values with 




did not affect mRNA levels of PRL, POMC or other CORT-regulated genes tested (Fig 
24). In a subsequent series of experiments, different doses of Dexras1 expression 
plasmids were also tested. 1ng to 1µg of Dexras1 expression plasmid were co-transfected 
(Fig 25). As seen before, 1µg of Dexras1 expression plasmid significantly decreased the 
CORT-dependent GH mRNA increase (Fig 25A; n=3, p<0.05). There was no affect of 
any other doses of plasmid (1ng, 10ng and 100ng) on CORT-induced GH mRNA levels 
(p>0.05). Under non-CORT-treated basal conditions, lower doses of Dexras1 plasmid 
(10ng and 100ng) significantly stimulated GH mRNA levels (Fig 25B; n=3, p<0.05). 
However, the effect of Dexras1 overexpression on GH mRNA was not as great as that 
seen with CORT. 
 
Downstream targets of Dexras1  
 Dexras1 has been implicated in regulating several signalling pathways, including 
MAPK signalling (190). MAPK signalling is also involved in CORT regulation of 
Dexras1, as shown in Fig 26. Furthermore, CORT induction of GH mRNA in chicken 
embryonic pituitary cells is blocked by inhibition of MEK1/2 (142). To identify if MAPK 
is a downstream target of Dexras1 in chickens, effect of overexpression of Dexras1 on 
phosphorylation of endogenous Elk-1 was examined in LMH and GH4C1 cells. Cells 
(GH4C1 and LMH) were transfected with empty pSport6.1 or Dexras1 expression plasmid 
for 6 h, and treated with CORT for 3 h. EGF treatment was included as a positive control, 
since EGF is known to increase phosphorylation of Elk-1. As shown in Fig 26 (A and B), 







Figure 25. Effect of overexpression of different doses of Dexras1 expression plasmid on 
GH mRNA levels. E11 chicken pituitary cells were transfected with indicated doses of 
Dexras1 expression plasmid, and treated with or without CORT (1nM). (A) GH mRNA 
levels. (B) GH mRNA levels under basal conditions alone. Values (Means+SEM) are 
presented normalized to beta-actin. Values with different letters denote significant 










        
 
Figure 26. Western blot analysis of effects of overexpression of Dexras1 on 
phosphorylation of endogenous Elk-1 in (A) GH4C1, and (B) LMH cells. 1µg of vector or 
Dexras1 plasmid was transfected into GH4C1 or LMH cells, which were then left 






Overexpression of Dexras1 did not affect phosphorylated Elk-1 levels in basal, EGF-, or 
CORT- treated samples in either cell type.   
Discussion 
We have characterized CORT regulation of Dexras1 expression in chicken 
pituitary cells and have attempted to identify a possible role of Dexras1 in regulating 
CORT-mediated GH gene expression. CORT regulation of GH in chicken anterior 
pituitary cells is an indirect effect (135), mediated through additional factors. The same is 
true for somatotroph differentiation and GH expression in rodents (125). These additional 
factors have not been identified in any species. A genome-wide microarray study was 
previously conducted in an effort to identify these factors (176). Dexras1 was identified 
as a potential candidate gene. In an independent experiment looking at involvement of 
cell signalling pathways in GH expression, a ras pathway or a ras-factor was shown to be 
essential (135). Dexras1 made an interesting candidate, considering that it is a ras protein 
and has a developmental expression profile similar to that of GH and CORT in chickens 
(140, 175, 176).  
If Dexras1 is involved in cell-type specific functions within the anterior pituitary, 
then expression of Dexras1 in these cells may be considered as a prerequisite. 
Endogenous Dexras1 expression in pituitary cells was therefore confirmed by two 
different methods. The FACS-based isolation of different pituitary cell types as well as 
the caudal-cephalic experiment results are consistent. Both experiments confirmed 
expression of Dexras1 in somatotroph and corticotroph cells of the e17 chicken pituitary 




not clearly detectable in our experiments. Very low levels of Dexras1 were detected in 
the thyrotrophs. In any case, it can be said that Dexras1 is expressed in multiple cell 
types, including somatotrophs and corticotrophs.  
The mechanism of CORT regulation of Dexras1 has not been defined in any 
species. Human Dexras1 has been shown to contain a GRE in its 3‘-flanking region, 
suggestive of a possible CORT-induction through the involvement of GR (229). The 
chicken Dexras1 gene on the other hand does not have a canonical GRE, but only half 
sites. In the present study, we investigated involvement of GR and MR in CORT 
induction of chicken Dexras1. We demonstrated that in embryonic chicken pituitary cells, 
CORT induction of Dexras1 is significantly reduced by blocking GR using a 
pharmacological inhibitor, confirming the participation of GR in the process. The MR 
inhibitor spironolactone had a different effect than the GR inhibitor. It is not clear if MR 
plays a role in Dexras1 expression. Blocking known signalling pathways indicated the 
need for a ras pathway or ras-like factors as well as MEK1/2 signalling for Dexras1 
induction by CORT, since UO126 and manumycin diminished the CORT effects on 
Dexras1 mRNA levels. No other pathways investigated had any effect on Dexras1 
mRNA levels. 
Next, we determined whether Dexras1 could influence CORT regulation of the 
GH gene. As a first step, we determined whether Dexras1 overexpression could modify 
promoter activity of the chicken GH gene. The -1727bp region of the chicken GH gene, 
identified as being CORT-responsive, was used as the reporter to measure whether the 
presence of Dexras1 can augment or attenuate CORT effects. In our study, Dexras1 




plasmid was tested. To test if overexpression of Dexras1 affects GH mRNA levels, cells 
transfected with Dexras1 were sorted using FACS, and GH mRNA levels were measured 
in sorted cells. Contrary to our hypothesis, Dexras1 overexpression inhibited CORT-
induced GH gene expression, at least when higher amounts of the expression plasmid 
were transfected. Interestingly, transfecting lower amounts of Dexras1 expression 
plasmid had a stimulatory effect on basal GH expression. Experiments were conducted 
with two doses of CORT, 1nM and 100nM, and both sets of experiments showed similar 
results. From these results, we can conclude that Dexras1 overexpression (at low levels) 
by itself increased GH gene expression. Dexras1 overexpression did not influence 
expression of other pituitary hormone genes (POMC and PRL) investigated, even though 
Dexras1 expression was found in both somatotrophs and corticotrophs. The mechanism 
of GH induction by Dexras1 is not yet clear.  
Dexras1 is a ras protein, and ras proteins are known to undergo post-translational 
modifications such as prenylation, which allows them to be translocated and attach to the 
plasma membrane (195). Although localization to the plasma membrane is not a 
necessary step for Dexras1 functioning in all cases, we still wanted to determine if CORT 
affects Dexras1 distribution within a cell. To this end, Dexras1 cellular localization was 
examined using aYFP-tagged fusion protein in GH4C1 rat pituitary cells and LMH cells. 
In GH4C1 cells, results suggest that Dexras1 may be predominantly found in the 
cytoplasm. There was no evident effect of CORT on Dexras1 localization. Functionality 
of Dexras1 was not tested in our experiments, although others have reported mixed 
results about localization of Dexras1, and this appears to be cell and function specific. 




activity is dependent on Dexras1 localization to the plasma membrane where it interacts 
with protein kinase C, PKCδ (188). Dexras1 has also been shown to bind to the amyloid 
beta precursor protein-binding member, FE65-PTB2 domain and potently suppress FE65-
APP (amyloid beta precursor protein)-mediated transcription. In this study, FE65 and 
Dexras1 were shown to colocalize in HEK cells, and FE65 increased Dexras1 
translocation from the cytosol to the nucleus (207). The subcellular localization of 
Dexras1 appears to be dependent on the cell type and to some extent on the interacting 
partners. Nevertheless, in LMH and GH4C1 rat pituitary cells, chicken Dexras1 
localization was not translocated to the plasma membrane in response to CORT.  
  Finally, we investigated the downstream effects of Dexras1. Previous studies 
have reported that CORT stimulation of GH transcription involves ERK1/2 siganlling, 
and CORT increases ERK1/2 activity after 3 h in cultured embryonic pituitary cells 
(142). We wanted to test if overexpression of Dexras1 could affect ERK1/2 activity, 
which was measured by the phosphorylation levels of Elk-1, a well-established 
downstream target of ERK1/2. Dexras1 overexpression did not significantly alter 
phosphorylation levels of Elk-1. Dexras1 has been shown to affect other signalling 
pathways (especially G-protein coupled receptor (GPCR) signalling) in other systems, 
and further experiments will have to be conducted to test downstream targets of Dexras1 
in pituitary cells.  
 Our study presents a novel role for Dexras1 in pituitary function. Dexras1 
expression has never been examined in embryonic tissues in other species. Our study 




corticotrophs and we found that Dexras1 can affect GH promoter activity and GH mRNA 












































The main aim of this study was to understand glucocorticoid regulation of GH 
gene expression in developing chickens. Glucocorticoid regulation of the GH gene is a 
complex process involving both genomic and non-genomic mechanisms. In this study, 
we addressed the involvement of histone modifications in association with transcription 
factor recruitment to the chicken GH gene, as well as investigated potential involvement 
of Dexras1 in mediating glucocorticoid-induced GH expression in chicken embryos. 
Epigenetic modifications play an integral part in regulating gene expression. 
Observations made in LSD1 knockout mice identified involvement of epigenetic 
processes in GH expression and somatotroph differentiation (1). Therefore, we 
hypothesized that glucocorticoid regulation of GH expression in chickens may occur 
through glucocorticoid-induced changes in histone modifications and transcription factor 
recruitment to the chicken GH promoter. It is also known that glucocorticoid induction of 
GH expression requires ongoing protein synthesis in chickens (135), which indicates that 
glucocorticoid induction of GH expression requires one or more additional factors. Pit-1 
is an essential transcription factor required for somatotroph differentiation (61), and the 
chicken GH promoter has two Pit-1 binding sites near the TSS (60). Glucocorticoids 
activate GR translocation to the nucleus, where GR regulates gene transcription by either 
directly binding to its GRE or by tethering to other transcriptional factors that have 
binding sites on DNA (104). In the chicken GH promoter, the GCRR with its Ets1 and 
GR binding sites is located near the distal Pit-1 binding site, which raises the possibility 
of GR interacting with Pit-1 and Ets1 factors. GR is known to interact with chromatin 
modifiers, such as SWI/SNF (160), CBP/p300 (224), etc. that have intrinsic HAT 




occupied by GR and Ets1. Similarly, the distal and proximal Pit-1 sites appear to be 
occupied by some Pit-1. We observed increased GR recruitment to the GCRR and the 
distal Pit-1 site in response to glucocorticoid treatment. We can speculate that GR may be 
recruited to the GCRR and the distal Pit-1 site as a part of a large complex. Factors, such 
as SWI/SNF, CBP/p300, etc. may be part of this complex. Additionally, Pit-1 and Ets1 
may transiently interact with GR at the GCRR or distal Pit-1 sites on DNA. It is also 
possible that glucocorticoid treatment increases GR recruitment as well as recruitment 
and association of chromatin modifiers, such as SWI/SNF, with GR, which is already 
present at the GCRR site. Furthermore, increased GR recruitment may be required for 
displacing Ets1 from its site in the GCRR, which may be necessary for the binding of 
additional factors to the chicken GH promoter. The increased GR recruitment to the distal 
Pit-1 site in response to glucocorticoid treatment may also explain the observed decrease 
in Pit-1 binding at the distal Pit-1 site.  
We believe that glucocorticoid-induced recruitment of GR to the GCRR and distal 
Pit-1 sites, Pit-1 to the proximal Pit-1 site, and the dissociation of Ets1 from the GCRR 
site allow recruitment and association of chromatin modifiers with the chicken GH gene. 
Once recruited, factors such as SWI/SNF, CBP/p300, etc. catalyze histone acetylation 
and tri-methylation of lysine 4 of histone H3 near the TSS of the chicken GH gene. 
Increased histone acetylation and tri-methylation of lysine 4 of histone H3 allows RNA 
Pol II and basal transcription factors to bind the TSS. By 6 h, we observe a decrease in 
histone acetylation and tri-methylation of lysine 4 at the TSS. We also observed 
dissociation of RNA Pol II from the TSS, Pit-1 from the proximal and distal Pit-1 sites, 




previously shown that HDAC activity is required for glucocorticoid-induction of GH 
expression at 6 h (142). The observed decrease in histone acetylation and tri-methylation 
with 6 h glucocorticoid treatment in our present study agrees with the previous results, 
and therefore supports the involvement of HDAC activity in glucocorticoid induction of 
GH expression.  
The identity of any HATs, HDACs, and HMTs involved in glucocorticoid 
induction of GH expression is yet to be established. CBP/p300 interaction with Pit-1 has 
been investigated in association with Pit-1 activity (232, 233), rendering CBP/p300 a 
possible candidate to be investigated. As a first step, coimmunoprecipitation studies 
looking at GR interaction with Pit-1, Ets1, and factors with HAT-activity, such as 
CBP/p300, need to be conducted. It is possible that these proteins interact with each other 
to form a large complex only in the presence of DNA. In addition, not all proteins within 
the complex may bind to DNA. For instance, GR or Pit-1 may be bind to DNA and act as 
mediators for other proteins. It is possible that GR and Pit-1 will not interact directly but 
through a larger complex. These questions will need further investigation to be able to 
understand the molecular details of glucocorticoid induction of GH expression. 
Reconstitution experiments using recombinant proteins could be conducted to answer 
some of these questions. Probe with the GCRR site sequence or the distal Pit-1 site 
sequence or both need to be included in the reconstitution experiments to confirm that 
these interactions do occur at these sites. Further, mutant GR or Pit-1 may be included in 
these studies to confirm interactions.   
As mentioned earlier, glucocorticoid regulation of GH expression in chickens 




involved in mediating glucocorticoid induction of GH expression. Dexras1 has only 
recently been identified as a glucocorticoid-regulated gene and remains to be 
characterized in context to pituitary functions. In the current study, glucocorticoid 
regulation of Dexras1 was characterized and a potential role for Dexras1 in regulating 
glucocorticoid-mediated GH expression in chickens was investigated. Glucocorticoid-
regulated Dexras1 expression requires GR and MEK1/2 signalling. Dexras1 mRNA is 
expressed in somatotroph and corticotroph cells of the anterior pituitary in chickens. 
Dexras1 was predominantly found in the cytoplasm, and cellular localization of Dexras1 
was not affected by glucocorticoid treatment. Transfection of 1µg of Dexras1 vector 
significantly decreased glucocorticoid-induced GH mRNA levels, while transfection of 
10ng and 100ng of Dexras1 vectors stimulated basal GH mRNA levels. These results 
indicate that Dexras1 has a potential role in glucocorticoid induction of GH expression in 
chickens. The mechanism of Dexras1 action is although not clearly understood. We 
attempted to investigate the effect of Dexras1 on GH secretion in chicken pituitary cells 
using reverse hemolytic plaque assays. However, we were unable to perform the assays 
due to potential low transfection efficiency of embryonic pituitary cells. In our present 
study, overexpression of Dexras1 had no effect on the phosphorylation of Elk-1. Dexras1 
overexpression also did not attenuate GH promoter activity. The mechanism involved in 
Dexras1 regulation of GH expression needs further investigation. To confirm 
involvement of Dexras1 in GH expression, Dexras1 knockdown experiments using 
siRNA will need to be conducted. Dexras1 may be indirectly regulating phosphorylation 




of Dexras1 on Pit-1 and GR phosphorylation. Effect of Dexras1 on histone modifications 
and transcription factor recruitment to the chicken GH gene may also be investigated.  
Dexras1 may be interacting with other proteins to regulate GH expression. 
Coimmunoprecipitation experiments to identify factors that interact with Dexras1 will 
provide insights into downstream targets of Dexras1. Factors known to interact with 
Dexras1 in other systems include carboxy-terminal PDZ ligand of nNOS (CAPON) 
(206), FE65-APP (207), etc. Dexras1 has been suggested to regulate secretion of 
hormone in AtT-20 cells (192).  Role of Dexras1 in regulating secretion of GH from 
chicken pituitary cells needs to be investigated. We have demonstrated that Dexras1 is 
expressed in somatotroph and corticotroph cells of the anterior pituitary in chickens, and 
therefore, Dexras1 may be involved in regulating multiple cell types in the anterior 
pituitary. Effect of Dexras1 on ACTH expression (both promoter activity and mRNA 
levels) and secretion will need to be further investigated.  
Overall, our present study has provided important insights into glucocorticoid-
mediated GH expression. It has demonstrated that glucocorticoids mediate dynamic 
changes in histone modifications and transcription factor binding to the endogenous GH 
gene. It has identified a potential novel role for Dexras1 in mediating glucocorticoid 
effects on GH expression in chickens. It provides a basis for future studies for better 
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